S-3ASR · 2026-11-05
Celldex Therapeutics has filed a registration statement to offer various securities, signaling potential capital-raising efforts for future projects.
| Name | Celldex Therapeutics, Inc. |
|---|---|
| CIK | 0000744218 |
| Tickers | CLDX |
| Exchanges | Nasdaq |
| Entity type | operating |
| Category | Large accelerated filer |
| SIC | 2835 In Vitro & In Vivo Diagnostic Substances |
| EIN | 133191702 |
| LEI | — |
| Fiscal year end | 1231 |
| State of incorporation | DE DE |
| Phone | 908-200-7500 |
| Website | — |
| Investor website | — |
| Owner org | 03 Life Sciences |
| Flags | — |
| Description | — |
| Insider transactions (issuer) | 1 |
| Insider transactions (owner) | 0 |
EDGAR has no company-logo API. Website field is shown when the filer provided one.
Celldex Therapeutics has filed a registration statement to offer various securities, signaling potential capital-raising efforts for future projects.
1299 filing rows loaded from submissions recent; extra archives: CIK0000744218-submissions-001.json (299 filings, 1995-04-06 to 2007-11-05).
| Filed | Form | Document | Items | Accession | File no. | Film | Act | Size | XBRL | iXBRL |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-16 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000902219-26-000376 | 005-37761 | 261557886 | 34 | 17593 | |||
| 2026-11-05 | S-3ASR | S-3ASR | 0001104659-26-123391 | 333-299858 | 261527999 | 33 | 592821 | 1 | 1 | |
| 2026-11-05 | 10-Q | 10-Q | 0001104659-26-123322 | 000-15006 | 261527246 | 34 | 7135027 | 1 | 1 | |
| 2026-11-05 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-26-007174 | 000-15006 | 261527011 | 34 | 293727 | 1 | 1 |
| 2026-10-07 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000315066-26-002325 | 005-37761 | 261446094 | 34 | 11973 | |||
| 2026-09-22 | 8-K | FORM 8-K | 8.01,9.01 | 0001104659-26-109465 | 000-15006 | 261395233 | 34 | 245657 | 1 | 1 |
| 2026-08-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001907884-26-000013 | 005-37761 | 261278482 | 34 | 9614 | |||
| 2026-08-14 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0000080255-26-000537 | 005-37761 | 261277428 | 34 | 7814 | |||
| 2026-08-06 | 10-Q | 10-Q | 0001104659-26-091984 | 000-15006 | 261248902 | 34 | 6679134 | 1 | 1 | |
| 2026-08-06 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-26-005316 | 000-15006 | 261248702 | 34 | 292293 | 1 | 1 |
| 2026-07-15 | 8-K | FORM 8-K | 5.02,9.01 | 0001104659-26-083880 | 000-15006 | 261177464 | 34 | 188085 | 1 | 1 |
| 2026-06-29 | 4 | xslF345X06/form4-06292026_080655.xml | 0001960596-26-000004 | 6034 | ||||||
| 2026-06-29 | 4 | xslF345X06/form4-06292026_080612.xml | 0001838114-26-000002 | 6048 | ||||||
| 2026-06-29 | 4 | xslF345X06/form4-06292026_080627.xml | 0001648010-26-000002 | 6039 | ||||||
| 2026-06-29 | 4 | xslF345X06/form4-06292026_080629.xml | 0001718112-26-000002 | 6054 | ||||||
| 2026-06-29 | 4 | xslF345X06/form4-06292026_080644.xml | 0001709024-26-000004 | 6048 | ||||||
| 2026-06-29 | 4 | xslF345X06/form4-06292026_080653.xml | 0001709113-26-000002 | 6049 | ||||||
| 2026-06-29 | 4 | xslF345X06/form4-06292026_080604.xml | 0001681854-26-000002 | 6043 | ||||||
| 2026-06-29 | 4 | xslF345X06/form4-06292026_080606.xml | 0001214504-26-000002 | 6033 | ||||||
| 2026-06-29 | 4 | xslF345X06/form4-06292026_080620.xml | 0001429931-26-000002 | 6029 | ||||||
| 2026-06-29 | 4 | xslF345X06/form4-06292026_080621.xml | 0001429933-26-000002 | 6044 | ||||||
| 2026-06-29 | 4 | xslF345X06/form4-06292026_080636.xml | 0001820278-26-000008 | 5777 | ||||||
| 2026-06-29 | 4 | xslF345X06/form4-06292026_080641.xml | 0001707797-26-000012 | 5825 | ||||||
| 2026-06-29 | 4 | xslF345X06/form4-06292026_080652.xml | 0001586785-26-000008 | 5847 | ||||||
| 2026-06-29 | 4 | xslF345X06/form4-06292026_080658.xml | 0001529371-26-000005 | 5828 | ||||||
| 2026-06-29 | 4 | xslF345X06/form4-06292026_080611.xml | 0001518575-26-000002 | 5838 | ||||||
| 2026-06-29 | 4 | xslF345X06/form4-06292026_080625.xml | 0001198578-26-000002 | 5832 | ||||||
| 2026-06-29 | 4 | xslF345X06/form4-06292026_080622.xml | 0001218815-26-000002 | 5838 | ||||||
| 2026-06-29 | 4 | xslF345X06/form4-06292026_080629.xml | 0001131148-26-000002 | 5839 | ||||||
| 2026-06-26 | S-8 | FORM S-8 | 0001104659-26-078233 | 333-297059 | 261128923 | 33 | 214339 | 1 | 1 | |
| 2026-06-26 | 8-K | FORM 8-K | 5.02,5.07,9.01 | 0001104659-26-078023 | 000-15006 | 261124002 | 34 | 226254 | 1 | 1 |
| 2026-05-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001907884-26-000009 | 005-37761 | 26986637 | 34 | 9621 | |||
| 2026-05-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001104659-26-062330 | 005-37761 | 26985868 | 34 | 10085 | |||
| 2026-05-12 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0000093751-26-000217 | 005-37761 | 26966445 | 34 | 8384 | |||
| 2026-05-07 | 10-Q | 10-Q | 0001104659-26-057113 | 000-15006 | 26953184 | 34 | 5794246 | 1 | 1 | |
| 2026-05-07 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-26-003153 | 000-15006 | 26952941 | 34 | 276320 | 1 | 1 |
| 2026-05-06 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000315066-26-001146 | 005-37761 | 26946620 | 34 | 11378 | |||
| 2026-04-29 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0002100119-26-000279 | 005-37761 | 26918298 | 34 | 7647 | |||
| 2026-04-29 | ARS | ARS | 0001104659-26-050885 | 000-15006 | 26910622 | 34 | 2731009 | |||
| 2026-04-29 | DEF 14A | FORM DEF 14A | 0001104659-26-050884 | 000-15006 | 26910609 | 34 | 5772763 | 1 | 1 | |
| 2026-04-02 | 424B5 | 424B5 | 0001104659-26-039255 | 333-275300 | 26835319 | 33 | 592885 | 1 | 1 | |
| 2026-04-02 | 8-K | FORM 8-K | 1.01,8.01,9.01 | 0001104659-26-038882 | 000-15006 | 26830707 | 34 | 592092 | 1 | 1 |
| 2026-04-01 | 424B5 | 424B5 | 0001104659-26-038501 | 333-275300 | 26828183 | 33 | 436058 | |||
| 2026-03-26 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000102909-26-000983 | 005-37761 | 26799452 | 34 | 7412 | |||
| 2026-03-10 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000902664-26-001544 | 005-37761 | 26740953 | 34 | 12382 | |||
| 2026-02-25 | 10-K | 10-K | 0001104659-26-019652 | 000-15006 | 26678501 | 34 | 10877826 | 1 | 1 | |
| 2026-02-25 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-26-001098 | 000-15006 | 26678336 | 34 | 296763 | 1 | 1 |
| 2026-02-10 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000902219-26-000058 | 005-37761 | 26614290 | 34 | 17450 | |||
| 2026-02-09 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0000093751-26-000033 | 005-37761 | 26609507 | 34 | 8279 | |||
| 2026-01-06 | 4 | xslF345X05/form4-01062026_090142.xml | 0001709024-26-000002 | 7076 | ||||||
| 2025-12-17 | 4 | xslF345X05/form4-12172025_091230.xml | 0001214504-25-000007 | 11536 | ||||||
| 2025-12-08 | 4 | xslF345X05/form4-12082025_091231.xml | 0001838114-25-000007 | 4856 | ||||||
| 2025-12-04 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-009745 | 000-15006 | 251549389 | 33 | 4958 | |||
| 2025-11-17 | 4 | xslF345X05/form4-11172025_091104.xml | 0001646423-25-000007 | 16537 | ||||||
| 2025-11-14 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001104659-25-112821 | 005-37761 | 251488965 | 34 | 9448 | |||
| 2025-11-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001831942-25-000031 | 005-37761 | 251488076 | 34 | 11704 | |||
| 2025-11-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000080255-25-000800 | 005-37761 | 251483432 | 34 | 7908 | |||
| 2025-11-13 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-008818 | 000-15006 | 251478682 | 33 | 4966 | |||
| 2025-11-12 | 4 | xslF345X05/form4-11122025_091122.xml | 0001960596-25-000008 | 5885 | ||||||
| 2025-11-12 | 3 | xslF345X02/form3-11122025_091156.xml | 0001960596-25-000006 | 8678 | ||||||
| 2025-11-10 | 10-Q | 10-Q | 0001104659-25-109137 | 000-15006 | 251466185 | 34 | 6958128 | 1 | 1 | |
| 2025-11-10 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-25-007179 | 000-15006 | 251466030 | 34 | 301129 | 1 | 1 |
| 2025-11-07 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000902219-25-000372 | 005-37761 | 251460621 | 34 | 17447 | |||
| 2025-08-19 | 8-K | FORM 8-K | 8.01,9.01 | 0001104659-25-080248 | 000-15006 | 251231708 | 34 | 230380 | 1 | 1 |
| 2025-08-15 | 4 | xslF345X05/form4-08152025_080825.xml | 0001415889-25-022069 | 6529 | ||||||
| 2025-08-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001580642-25-005132 | 005-37761 | 251217829 | 34 | 11933 | |||
| 2025-08-12 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000902219-25-000286 | 005-37761 | 251204926 | 34 | 17452 | |||
| 2025-08-07 | 10-Q | 10-Q | 0001410578-25-001610 | 000-15006 | 251193941 | 34 | 6519173 | 1 | 1 | |
| 2025-08-07 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-25-005181 | 000-15006 | 251193791 | 34 | 280976 | 1 | 1 |
| 2025-07-10 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0000902664-25-002963 | 005-37761 | 251116439 | 34 | 18232 | |||
| 2025-06-09 | 4 | xslF345X05/form4-06092025_080647.xml | 0001415889-25-016260 | 5911 | ||||||
| 2025-06-09 | 4 | xslF345X05/form4-06092025_080605.xml | 0001415889-25-016257 | 5902 | ||||||
| 2025-06-09 | 4 | xslF345X05/form4-06092025_080648.xml | 0001415889-25-016255 | 5916 | ||||||
| 2025-06-09 | 4 | xslF345X05/form4-06092025_080659.xml | 0001415889-25-016244 | 5910 | ||||||
| 2025-06-09 | 4 | xslF345X05/form4-06092025_080614.xml | 0001415889-25-016242 | 5910 | ||||||
| 2025-06-09 | 4 | xslF345X05/form4-06092025_080610.xml | 0001415889-25-016241 | 5895 | ||||||
| 2025-06-09 | 4 | xslF345X05/form4-06092025_080613.xml | 0001415889-25-016238 | 5901 | ||||||
| 2025-06-09 | 4 | xslF345X05/form4-06092025_080623.xml | 0001415889-25-016230 | 5888 | ||||||
| 2025-06-09 | 4 | xslF345X05/form4-06092025_080629.xml | 0001415889-25-016227 | 5906 | ||||||
| 2025-06-09 | 4 | xslF345X05/form4-06092025_080642.xml | 0001415889-25-016226 | 5750 | ||||||
| 2025-06-09 | 4 | xslF345X05/form4-06092025_080641.xml | 0001415889-25-016225 | 5688 | ||||||
| 2025-06-09 | 4 | xslF345X05/form4-06092025_080657.xml | 0001415889-25-016222 | 5710 | ||||||
| 2025-06-09 | 4 | xslF345X05/form4-06092025_080604.xml | 0001415889-25-016220 | 5702 | ||||||
| 2025-06-09 | 4 | xslF345X05/form4-06092025_080631.xml | 0001415889-25-016219 | 5701 | ||||||
| 2025-06-09 | 4 | xslF345X05/form4-06092025_080645.xml | 0001415889-25-016217 | 5695 | ||||||
| 2025-06-09 | 4 | xslF345X05/form4-06092025_080604.xml | 0001415889-25-016216 | 5701 | ||||||
| 2025-06-09 | 4 | xslF345X05/form4-06092025_080601.xml | 0001415889-25-016215 | 5691 | ||||||
| 2025-06-06 | S-8 | FORM S-8 | 0001104659-25-057296 | 333-287839 | 251030450 | 33 | 186835 | 1 | 1 | |
| 2025-06-06 | 3 | OWNERSHIP DOCUMENT | 0001104659-25-057069 | 8365 | ||||||
| 2025-06-06 | 8-K | FORM 8-K | 5.02,5.07,9.01 | 0001104659-25-057066 | 000-15006 | 251028926 | 34 | 250389 | 1 | 1 |
| 2025-05-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001085146-25-003253 | 005-37761 | 25950311 | 34 | 9539 | |||
| 2025-05-12 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000902219-25-000176 | 005-37761 | 25933439 | 34 | 17430 | |||
| 2025-05-08 | 10-Q | 10-Q | 0001410578-25-001111 | 000-15006 | 25925986 | 34 | 5699720 | 1 | 1 | |
| 2025-05-08 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-25-002980 | 000-15006 | 25925821 | 34 | 274591 | 1 | 1 |
| 2025-04-21 | ARS | ARS | 0001104659-25-036833 | 000-15006 | 25853185 | 34 | 19805086 | |||
| 2025-04-21 | DEF 14A | FORM DEF 14A | 0001104659-25-036562 | 000-15006 | 25851334 | 34 | 5933590 | 1 | 1 | |
| 2025-04-17 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001576419-25-000573 | 005-37761 | 25844512 | 34 | 11253 | |||
| 2025-04-10 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001641172-25-003604 | 005-37761 | 25828341 | 34 | 17620 | |||
| 2025-02-27 | 10-K | 10-K | 0001410578-25-000216 | 000-15006 | 25678667 | 34 | 9188778 | 1 | 1 | |
| 2025-02-27 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-25-001126 | 000-15006 | 25678504 | 34 | 291336 | 1 | 1 |
| 2025-02-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001085146-25-001723 | 005-37761 | 25630916 | 34 | 9629 | |||
| 2025-02-14 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0000080255-25-000177 | 005-37761 | 25624046 | 34 | 7713 | |||
| 2025-02-12 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000315066-25-000856 | 005-37761 | 25612540 | 34 | 11811 | |||
| 2025-02-05 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0002012383-25-001193 | 005-37761 | 25592180 | 34 | 12302 | |||
| 2024-11-20 | 4 | xslF345X05/form4-11202024_091142.xml | 0001415889-24-027329 | 5054 | ||||||
| 2024-11-14 | SC 13G/A | p24-3151sc13ga.htm | 0000902664-24-006640 | 005-37761 | 241465284 | 34 | 63770 | |||
| 2024-11-14 | SC 13G/A | SC 13G/A | 0001580642-24-006951 | 005-37761 | 241459279 | 34 | 56540 | |||
| 2024-11-14 | SC 13G/A | CELLDEX THERAPEUTICS, INC. | 0000902664-24-006486 | 005-37761 | 241456852 | 34 | 64381 | |||
| 2024-11-13 | SC 13G/A | polar-cldx093024a1.htm | 0001172661-24-004709 | 005-37761 | 241456004 | 34 | 88114 | |||
| 2024-11-12 | SC 13G/A | filing.txt | 0000315066-24-002724 | 005-37761 | 241444515 | 34 | 8453 | |||
| 2024-11-12 | 4 | xslF345X05/form4-11122024_011107.xml | 0001415889-24-026489 | 5007 | ||||||
| 2024-11-08 | SC 13G/A | SEC SCHEDULE 13G | 0000902219-24-000467 | 005-37761 | 241438666 | 34 | 36391 | |||
| 2024-11-06 | 10-Q | 10-Q | 0001410578-24-001766 | 000-15006 | 241430907 | 34 | 6163566 | 1 | 1 | |
| 2024-11-06 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-24-006056 | 000-15006 | 241430782 | 34 | 278222 | 1 | 1 |
| 2024-08-08 | 10-Q | 10-Q | 0001410578-24-001219 | 000-15006 | 241188191 | 34 | 5828844 | 1 | 1 | |
| 2024-08-08 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-24-004603 | 000-15006 | 241188051 | 34 | 300601 | 1 | 1 |
| 2024-06-18 | 4 | xslF345X05/form4-06182024_080610.xml | 0001415889-24-017363 | 12800 | ||||||
| 2024-06-18 | 4 | xslF345X05/form4-06182024_080610.xml | 0001415889-24-017362 | 9109 | ||||||
| 2024-06-17 | 4 | xslF345X05/form4-06172024_080643.xml | 0001415889-24-017190 | 5918 | ||||||
| 2024-06-17 | 4 | xslF345X05/form4-06172024_080635.xml | 0001415889-24-017186 | 5866 | ||||||
| 2024-06-17 | 4 | xslF345X05/form4-06172024_080655.xml | 0001415889-24-017184 | 5924 | ||||||
| 2024-06-17 | 4 | xslF345X05/form4-06172024_080619.xml | 0001415889-24-017182 | 5919 | ||||||
| 2024-06-17 | 4 | xslF345X05/form4-06172024_080638.xml | 0001415889-24-017179 | 5910 | ||||||
| 2024-06-17 | 4 | xslF345X05/form4-06172024_080608.xml | 0001415889-24-017177 | 5909 | ||||||
| 2024-06-17 | 4 | xslF345X05/form4-06172024_080640.xml | 0001415889-24-017175 | 5870 | ||||||
| 2024-06-17 | 4 | xslF345X05/form4-06172024_080654.xml | 0001415889-24-017163 | 5918 | ||||||
| 2024-06-17 | 4 | xslF345X05/form4-06172024_080615.xml | 0001415889-24-017161 | 5840 | ||||||
| 2024-06-17 | 4 | xslF345X05/form4-06172024_080622.xml | 0001415889-24-017159 | 5862 | ||||||
| 2024-06-17 | 4 | xslF345X05/form4-06172024_080640.xml | 0001415889-24-017158 | 5698 | ||||||
| 2024-06-17 | 4 | xslF345X05/form4-06172024_080651.xml | 0001415889-24-017155 | 5692 | ||||||
| 2024-06-17 | 4 | xslF345X05/form4-06172024_080620.xml | 0001415889-24-017153 | 5692 | ||||||
| 2024-06-17 | 4 | xslF345X05/form4-06172024_080643.xml | 0001415889-24-017151 | 5665 | ||||||
| 2024-06-17 | 4 | xslF345X05/form4-06172024_080622.xml | 0001415889-24-017141 | 5687 | ||||||
| 2024-06-17 | 4 | xslF345X05/form4-06172024_080647.xml | 0001415889-24-017140 | 5706 | ||||||
| 2024-06-17 | 4 | xslF345X05/form4-06172024_080614.xml | 0001415889-24-017138 | 5743 | ||||||
| 2024-06-17 | 4 | xslF345X05/form4-06172024_080638.xml | 0001415889-24-017137 | 5700 | ||||||
| 2024-06-14 | 144 | xsl144X01/primary_doc.xml | 0001972362-24-000916 | 000-15006 | 241046152 | 33 | 6364 | |||
| 2024-06-14 | 144 | xsl144X01/primary_doc.xml | 0001972362-24-000913 | 000-15006 | 241045932 | 33 | 6866 | |||
| 2024-06-14 | S-8 | FORM S-8 | 0001104659-24-071737 | 333-280207 | 241044611 | 33 | 92022 | |||
| 2024-06-14 | 8-K | FORM 8-K | 5.02,5.07,9.01 | 0001104659-24-071512 | 000-15006 | 241043176 | 34 | 231090 | 1 | 1 |
| 2024-06-13 | 4 | xslF345X05/form4-06132024_080617.xml | 0001415889-24-016651 | 7013 | ||||||
| 2024-06-11 | 4 | xslF345X05/form4-06112024_080653.xml | 0001415889-24-016345 | 12852 | ||||||
| 2024-06-11 | 4 | xslF345X05/form4-06112024_080650.xml | 0001415889-24-016344 | 5373 | ||||||
| 2024-06-07 | 144 | xsl144X01/primary_doc.xml | 0001972362-24-000871 | 000-15006 | 241030745 | 33 | 4453 | |||
| 2024-06-07 | 144 | xsl144X01/primary_doc.xml | 0001972362-24-000866 | 000-15006 | 241030420 | 33 | 5844 | |||
| 2024-06-07 | 4 | xslF345X05/form4-06072024_080609.xml | 0001415889-24-015950 | 7148 | ||||||
| 2024-06-05 | 4 | xslF345X05/form4-06052024_080636.xml | 0001415889-24-015544 | 12950 | ||||||
| 2024-06-05 | 4 | xslF345X05/form4-06052024_080641.xml | 0001415889-24-015543 | 18791 | ||||||
| 2024-06-05 | 4 | xslF345X05/form4-06052024_080652.xml | 0001415889-24-015542 | 8622 | ||||||
| 2024-06-03 | 144 | xsl144X01/primary_doc.xml | 0001972362-24-000831 | 000-15006 | 241015275 | 33 | 4508 | |||
| 2024-06-03 | 144 | xsl144X01/primary_doc.xml | 0001972362-24-000827 | 000-15006 | 241014866 | 33 | 4511 | |||
| 2024-06-03 | 4 | xslF345X05/form4-06032024_080622.xml | 0001415889-24-015148 | 16830 | ||||||
| 2024-06-03 | 4 | xslF345X05/form4-06032024_080645.xml | 0001415889-24-015147 | 9262 | ||||||
| 2024-06-03 | 4 | xslF345X05/form4-06032024_080652.xml | 0001415889-24-015138 | 13074 | ||||||
| 2024-06-03 | 4 | xslF345X05/form4-06032024_080604.xml | 0001415889-24-015137 | 12870 | ||||||
| 2024-05-30 | 144 | xsl144X01/primary_doc.xml | 0001972362-24-000812 | 000-15006 | 241006970 | 33 | 4504 | |||
| 2024-05-30 | 144 | xsl144X01/primary_doc.xml | 0001972362-24-000811 | 000-15006 | 241006963 | 33 | 7117 | |||
| 2024-05-30 | 144 | xsl144X01/primary_doc.xml | 0001972362-24-000809 | 000-15006 | 241006918 | 33 | 5040 | |||
| 2024-05-30 | 144 | xsl144X01/primary_doc.xml | 0001972362-24-000804 | 000-15006 | 241004450 | 33 | 5049 | |||
| 2024-05-06 | 10-Q | 10-Q | 0001410578-24-000593 | 000-15006 | 24917532 | 34 | 5227772 | 1 | 1 | |
| 2024-05-06 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-24-002570 | 000-15006 | 24917393 | 34 | 268854 | 1 | 1 |
| 2024-04-25 | ARS | ARS | 0001104659-24-051958 | 000-15006 | 24876200 | 34 | 2506786 | |||
| 2024-04-25 | DEF 14A | DEF 14A | 0001104659-24-051634 | 000-15006 | 24873064 | 34 | 3599893 | 1 | 1 | |
| 2024-03-01 | 8-K | FORM 8-K | 1.01,8.01,9.01 | 0001104659-24-029969 | 000-15006 | 24709756 | 34 | 625595 | 1 | 1 |
| 2024-03-01 | 424B5 | 424B5 | 0001104659-24-029958 | 333-275300 | 24709714 | 33 | 459381 | |||
| 2024-02-28 | 424B5 | 424B5 | 0001104659-24-028718 | 333-275300 | 24695422 | 33 | 418032 | |||
| 2024-02-26 | 424B5 | 424B5 | 0001104659-24-027306 | 333-275300 | 24673635 | 33 | 390027 | |||
| 2024-02-26 | 10-K | 10-K | 0001410578-24-000076 | 000-15006 | 24673521 | 34 | 8867514 | 1 | 1 | |
| 2024-02-26 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-24-000966 | 000-15006 | 24673512 | 34 | 292085 | 1 | 1 |
| 2024-02-15 | 4 | xslF345X05/form4-02152024_090240.xml | 0001415889-24-003891 | 11513 | ||||||
| 2024-02-14 | SC 13G/A | CELLDEX THERAPEUTICS, INC. | 0000902664-24-001707 | 005-37761 | 24638560 | 34 | 66374 | |||
| 2024-02-14 | SC 13G | KYNAM CAPITAL MANAGEMENT, LP | 0001085146-24-001357 | 005-37761 | 24635202 | 34 | 44356 | |||
| 2024-02-14 | SC 13G | SC 13G | 0001580642-24-000979 | 005-37761 | 24634622 | 34 | 55399 | |||
| 2024-02-14 | SC 13G/A | CELLDEX THERAPEUTICS, INC. | 0000902664-24-001565 | 005-37761 | 24632339 | 34 | 63553 | |||
| 2024-02-13 | SC 13G/A | SCHEDULE 13G/A | 0001104659-24-020559 | 005-37761 | 24627676 | 34 | 13293 | |||
| 2024-02-13 | SC 13G | polar-cldx123123.htm | 0001172661-24-000763 | 005-37761 | 24623003 | 34 | 88096 | |||
| 2024-02-09 | SC 13G/A | filing.txt | 0000315066-24-001069 | 005-37761 | 24611506 | 34 | 8456 | |||
| 2024-02-08 | SC 13G/A | SEC SCHEDULE 13G | 0000902219-24-000057 | 005-37761 | 24607279 | 34 | 38189 | |||
| 2024-01-26 | SC 13G/A | us15117b2025_012624.txt | 0001086364-24-004828 | 005-37761 | 24569151 | 34 | 13861 | |||
| 2024-01-04 | 4 | xslF345X05/form4-01042024_090138.xml | 0001415889-24-000592 | 7080 | ||||||
| 2023-11-20 | SC 13G | CELLDEX THERAPEUTICS, INC. | 0000902664-23-005657 | 005-37761 | 231422917 | 34 | 71028 | |||
| 2023-11-08 | 8-K | FORM 8-K | 1.01,8.01,9.01 | 0001104659-23-115796 | 000-15006 | 231389089 | 34 | 622392 | 1 | 1 |
| 2023-11-08 | 424B5 | 424B5 | 0001104659-23-115792 | 333-275300 | 231389067 | 33 | 527250 | |||
| 2023-11-07 | 424B5 | 424B5 | 0001104659-23-115217 | 333-275300 | 231383547 | 33 | 488250 | |||
| 2023-11-06 | 8-K | FORM 8-K | 8.01 | 0001104659-23-114520 | 000-15006 | 231378497 | 34 | 215649 | 1 | 1 |
| 2023-11-03 | S-3ASR | S-3ASR | 0001104659-23-114270 | 333-275300 | 231376228 | 33 | 290025 | |||
| 2023-11-02 | 10-Q | 10-Q | 0001410578-23-002169 | 000-15006 | 231372234 | 34 | 5978718 | 1 | 1 | |
| 2023-11-02 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-23-006668 | 000-15006 | 231372054 | 34 | 294932 | 1 | 1 |
| 2023-08-08 | 10-Q | 10-Q | 0001410578-23-001588 | 000-15006 | 231151232 | 34 | 5692634 | 1 | 1 | |
| 2023-08-08 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-23-005101 | 000-15006 | 231151047 | 34 | 292838 | 1 | 1 |
| 2023-06-21 | S-8 | FORM S-8 | 0001104659-23-073322 | 333-272804 | 231029855 | 33 | 70821 | |||
| 2023-06-20 | 4 | xslF345X04/form4-06202023_080658.xml | 0001415889-23-010049 | 5784 | ||||||
| 2023-06-20 | 4 | xslF345X04/form4-06202023_080633.xml | 0001415889-23-010048 | 5833 | ||||||
| 2023-06-20 | 4 | xslF345X04/form4-06202023_080630.xml | 0001415889-23-010047 | 5794 | ||||||
| 2023-06-20 | 4 | xslF345X04/form4-06202023_080654.xml | 0001415889-23-010046 | 5836 | ||||||
| 2023-06-20 | 4 | xslF345X04/form4-06202023_080605.xml | 0001415889-23-010045 | 5836 | ||||||
| 2023-06-20 | 4 | xslF345X04/form4-06202023_080633.xml | 0001415889-23-010044 | 5842 | ||||||
| 2023-06-20 | 4 | xslF345X04/form4-06202023_080649.xml | 0001415889-23-010043 | 5830 | ||||||
| 2023-06-20 | 4 | xslF345X04/form4-06202023_080654.xml | 0001415889-23-010042 | 5837 | ||||||
| 2023-06-20 | 4 | xslF345X04/form4-06202023_080658.xml | 0001415889-23-010041 | 5764 | ||||||
| 2023-06-20 | 4 | xslF345X04/form4-06202023_080657.xml | 0001415889-23-010039 | 5786 | ||||||
| 2023-06-20 | 4 | xslF345X04/form4-06202023_080621.xml | 0001415889-23-010038 | 5589 | ||||||
| 2023-06-20 | 4 | xslF345X04/form4-06202023_080641.xml | 0001415889-23-010037 | 5624 | ||||||
| 2023-06-20 | 4 | xslF345X04/form4-06202023_080604.xml | 0001415889-23-010036 | 5610 | ||||||
| 2023-06-20 | 4 | xslF345X04/form4-06202023_080610.xml | 0001415889-23-010035 | 5611 | ||||||
| 2023-06-20 | 4 | xslF345X04/form4-06202023_080626.xml | 0001415889-23-010034 | 5630 | ||||||
| 2023-06-20 | 4 | xslF345X04/form4-06202023_080641.xml | 0001415889-23-010033 | 5610 | ||||||
| 2023-06-20 | 4 | xslF345X04/form4-06202023_080655.xml | 0001415889-23-010032 | 5667 | ||||||
| 2023-06-15 | 8-K | FORM 8-K | 5.07,9.01 | 0001104659-23-071597 | 000-15006 | 231017331 | 34 | 234938 | 1 | 1 |
| 2023-05-10 | SC 13G/A | SEC SCHEDULE 13G | 0000902219-23-000024 | 005-37761 | 23904514 | 34 | 38072 | |||
| 2023-05-04 | 10-Q | FORM 10-Q | 0001104659-23-055992 | 000-15006 | 23888593 | 34 | 4972317 | 1 | 1 | |
| 2023-05-04 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-23-002887 | 000-15006 | 23888456 | 34 | 272420 | 1 | 1 |
| 2023-04-25 | ARS | ARS | 0001104659-23-049609 | 000-15006 | 23844853 | 34 | 3449355 | |||
| 2023-04-25 | DEF 14A | DEF 14A | 0001104659-23-049299 | 000-15006 | 23841804 | 34 | 6882382 | 1 | 1 | |
| 2023-03-22 | 8-K | FORM 8-K | 8.01 | 0001104659-23-035198 | 000-15006 | 23750851 | 34 | 206664 | 1 | 1 |
| 2023-02-28 | 10-K | FORM 10-K | 0001104659-23-026701 | 000-15006 | 23685135 | 34 | 8466247 | 1 | 1 | |
| 2023-02-28 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-23-001254 | 000-15006 | 23685031 | 34 | 308847 | 1 | 1 |
| 2023-02-21 | 4 | xslF345X03/ownership.xml | 0001493152-23-005663 | 5686 | ||||||
| 2023-02-21 | 3 | xslF345X02/ownership.xml | 0001493152-23-005658 | 12046 | ||||||
| 2023-02-21 | 8-K | FORM 8-K | 5.02,7.01,9.01 | 0001104659-23-023768 | 000-15006 | 23647986 | 34 | 229207 | 1 | 1 |
| 2023-02-14 | SC 13G/A | SC 13G/A | 0001140361-23-006807 | 005-37761 | 23626272 | 34 | 327249 | |||
| 2023-02-14 | SC 13G/A | CELLDEX THERAPEUTICS, INC. | 0000902664-23-001725 | 005-37761 | 23623860 | 34 | 62520 | |||
| 2023-02-09 | SC 13G/A | SCHEDULE 13G/A | 0001104659-23-015586 | 005-37761 | 23602705 | 34 | 13212 | |||
| 2023-02-09 | SC 13G/A | filing.txt | 0000315066-23-001436 | 005-37761 | 23601745 | 34 | 8374 | |||
| 2023-02-06 | SC 13G | SEC SCHEDULE 13G | 0000846087-23-000092 | 005-37761 | 23590061 | 34 | 38151 | |||
| 2023-02-01 | SC 13G/A | Celldex_Therapeutics_Inc.txt | 0000093751-23-000067 | 005-37761 | 23575126 | 34 | 8668 | |||
| 2023-02-01 | SC 13G/A | us15117b2025_013123.txt | 0001306550-23-005854 | 005-37761 | 23573863 | 34 | 13604 | |||
| 2022-12-09 | 4 | xslF345X03/form4-12092022_091203.xml | 0001415889-22-012301 | 9049 | ||||||
| 2022-11-09 | 10-Q | FORM 10-Q | 0001104659-22-116466 | 000-15006 | 221372563 | 34 | 6765086 | 1 | 1 | |
| 2022-11-09 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-22-007291 | 000-15006 | 221372446 | 34 | 297783 | 1 | 1 |
| 2022-08-19 | 4 | xslF345X03/form4-08192022_010836.xml | 0001415889-22-008896 | 14946 | ||||||
| 2022-08-19 | 4 | xslF345X03/form4-08192022_010835.xml | 0001415889-22-008895 | 12733 | ||||||
| 2022-08-17 | 4 | xslF345X03/form4-08172022_010842.xml | 0001415889-22-008769 | 13230 | ||||||
| 2022-08-17 | 4 | xslF345X03/form4-08172022_010827.xml | 0001415889-22-008767 | 9048 | ||||||
| 2022-08-15 | 4 | xslF345X03/form4-08152022_010833.xml | 0001415889-22-008608 | 22440 | ||||||
| 2022-08-08 | 10-Q | FORM 10-Q | 0001104659-22-087222 | 000-15006 | 221144349 | 34 | 5816663 | 1 | 1 | |
| 2022-08-08 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-22-005457 | 000-15006 | 221144226 | 34 | 307729 | 1 | 1 |
| 2022-07-18 | 8-K | FORM 8-K | 1.01,9.01 | 0001104659-22-080483 | 000-15006 | 221089214 | 34 | 270828 | 1 | 1 |
| 2022-06-23 | 8-K | FORM 8-K | 1.01,2.02,9.01 | 0001104659-22-073889 | 000-15006 | 221035432 | 34 | 239489 | 1 | 1 |
| 2022-06-17 | 4 | xslF345X03/form4-06172022_010604.xml | 0001415889-22-006733 | 5801 | ||||||
| 2022-06-17 | 4 | xslF345X03/form4-06172022_010617.xml | 0001415889-22-006732 | 5804 | ||||||
| 2022-06-17 | 4 | xslF345X03/form4-06172022_010609.xml | 0001415889-22-006731 | 5805 | ||||||
| 2022-06-17 | 4 | xslF345X03/form4-06172022_010602.xml | 0001415889-22-006728 | 5810 | ||||||
| 2022-06-17 | 4 | xslF345X03/form4-06172022_010610.xml | 0001415889-22-006726 | 5752 | ||||||
| 2022-06-17 | 4 | xslF345X03/form4-06172022_010627.xml | 0001415889-22-006722 | 5798 | ||||||
| 2022-06-17 | 4 | xslF345X03/form4-06172022_010626.xml | 0001415889-22-006718 | 5804 | ||||||
| 2022-06-17 | 4 | xslF345X03/form4-06172022_010613.xml | 0001415889-22-006716 | 5762 | ||||||
| 2022-06-17 | 4 | xslF345X03/form4-06172022_010651.xml | 0001415889-22-006712 | 5732 | ||||||
| 2022-06-17 | 4 | xslF345X03/form4-06172022_010652.xml | 0001415889-22-006709 | 5754 | ||||||
| 2022-06-17 | 4 | xslF345X03/form4-06172022_010605.xml | 0001415889-22-006708 | 5592 | ||||||
| 2022-06-17 | 4 | xslF345X03/form4-06172022_010604.xml | 0001415889-22-006705 | 5598 | ||||||
| 2022-06-17 | 4 | xslF345X03/form4-06172022_010653.xml | 0001415889-22-006700 | 5557 | ||||||
| 2022-06-17 | 4 | xslF345X03/form4-06172022_010659.xml | 0001415889-22-006696 | 5579 | ||||||
| 2022-06-17 | 4 | xslF345X03/ownership.xml | 0001493152-22-017153 | 5684 | ||||||
| 2022-06-17 | 4 | xslF345X03/ownership.xml | 0001493152-22-017154 | 5684 | ||||||
| 2022-06-17 | 4 | xslF345X03/form4-06172022_010651.xml | 0001415889-22-006694 | 5635 | ||||||
| 2022-06-17 | 3 | xslF345X02/ownership.xml | 0001493152-22-017138 | 12057 | ||||||
| 2022-06-17 | 3 | xslF345X02/ownership.xml | 0001493152-22-017139 | 12605 | ||||||
| 2022-06-16 | 8-K | FORM 8-K | 5.07 | 0001104659-22-071880 | 000-15006 | 221020579 | 34 | 202895 | 1 | 1 |
| 2022-06-10 | SC 13G | SC 13G | 0001140361-22-022594 | 005-37761 | 221009060 | 34 | 353903 | |||
| 2022-05-05 | 10-Q | 10-Q | 0001104659-22-056442 | 000-15006 | 22896164 | 34 | 5145924 | 1 | 1 | |
| 2022-05-05 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-22-003323 | 000-15006 | 22896021 | 34 | 266233 | 1 | 1 |
| 2022-04-26 | DEF 14A | DEF 14A | 0001104659-22-049942 | 000-15006 | 22851720 | 34 | 1521269 | |||
| 2022-02-28 | 10-K | FORM 10K | 0001104659-22-028070 | 000-15006 | 22689341 | 34 | 8423851 | 1 | 1 | |
| 2022-02-28 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-22-001448 | 000-15006 | 22689213 | 34 | 313727 | 1 | 1 |
| 2022-02-14 | SC 13G/A | SC 13G/A | 0001104659-22-023142 | 005-37761 | 22634480 | 34 | 68856 | |||
| 2022-02-14 | SC 13G/A | CELLDEX THERAPEUTICS, INC. | 0000902664-22-001595 | 005-37761 | 22625696 | 34 | 60865 | |||
| 2022-02-10 | SC 13G | CELLDEX_THERAPEUTICS_INC.txt | 0000093751-22-000124 | 005-37761 | 22612847 | 34 | 8687 | |||
| 2022-02-10 | SC 13G/A | CELLDEX THERAPEUTICS, INC. | 0000902664-22-001350 | 005-37761 | 22611430 | 34 | 102208 | |||
| 2022-02-09 | SC 13G | SCHEDULE 13G | 0001104659-22-016770 | 005-37761 | 22606751 | 34 | 13179 | |||
| 2022-02-09 | SC 13G/A | filing.txt | 0000315066-22-000887 | 005-37761 | 22604221 | 34 | 8657 | |||
| 2022-02-04 | SC 13G | us15117b2025_020422.txt | 0000834237-22-007115 | 005-37761 | 22593338 | 34 | 13598 | |||
| 2022-01-28 | 8-K | FORM 8-K | 5.03,9.01 | 0001104659-22-008977 | 000-15006 | 22568704 | 34 | 269207 | 1 | 1 |
| 2022-01-18 | SC 13G/A | COWEN FINANCIAL PRODUCTS LLC | 0001085146-22-000165 | 005-37761 | 22535523 | 34 | 27383 | |||
| 2022-01-14 | SC 13G/A | COWEN FINANCIAL PRODUCTS LLC | 0001085146-22-000137 | 005-37761 | 22531391 | 34 | 27247 | |||
| 2021-12-28 | 4 | FORM 4 - | 0001179110-21-011251 | 12034 | ||||||
| 2021-12-10 | 4 | FORM 4 - | 0001179110-21-010820 | 12048 | ||||||
| 2021-12-10 | 4 | FORM 4 - | 0001179110-21-010819 | 9022 | ||||||
| 2021-12-10 | 4 | FORM 4 - | 0001179110-21-010818 | 8514 | ||||||
| 2021-11-17 | 4 | FORM 4 - | 0001179110-21-010208 | 14594 | ||||||
| 2021-11-16 | 4 | FORM 4 - | 0001179110-21-010165 | 8735 | ||||||
| 2021-11-09 | 10-Q | 10-Q | 0001104659-21-136268 | 000-15006 | 211392068 | 34 | 6231488 | 1 | 1 | |
| 2021-11-09 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-21-007741 | 000-15006 | 211391929 | 34 | 301689 | 1 | 1 |
| 2021-11-03 | 4 | FORM 4 - | 0001179110-21-009818 | 17474 | ||||||
| 2021-11-03 | 4 | FORM 4 - | 0001179110-21-009816 | 13396 | ||||||
| 2021-11-03 | 4 | FORM 4 - | 0001179110-21-009815 | 8514 | ||||||
| 2021-10-12 | SC 13G | filing.txt | 0000315066-21-001801 | 005-37761 | 211317259 | 34 | 8649 | |||
| 2021-08-13 | 4 | FORM 4 - | 0001179110-21-008164 | 7630 | ||||||
| 2021-08-13 | 4 | FORM 4 - | 0001179110-21-008163 | 4681 | ||||||
| 2021-08-12 | 4 | FORM 4 - | 0001179110-21-008140 | 14115 | ||||||
| 2021-08-09 | 4 | FORM 4 - | 0001179110-21-008010 | 7581 | ||||||
| 2021-08-05 | 10-Q | 10-Q | 0001104659-21-100745 | 000-15006 | 211148163 | 34 | 5817278 | 1 | 1 | |
| 2021-08-05 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-21-005572 | 000-15006 | 211148052 | 34 | 91494 | ||
| 2021-07-15 | 424B5 | 424B5 | 0001104659-21-092200 | 333-249917 | 211091310 | 33 | 751997 | |||
| 2021-07-14 | 8-K | FORM 8-K | 1.01,8.01,9.01 | 0001104659-21-092099 | 000-15006 | 211090291 | 34 | 368023 | ||
| 2021-07-12 | 424B5 | 424B5 | 0001104659-21-091181 | 333-249917 | 211085766 | 33 | 740162 | |||
| 2021-07-12 | 8-K | FORM 8-K | 8.01 | 0001104659-21-091151 | 000-15006 | 211085559 | 34 | 30407 | ||
| 2021-07-01 | 8-K | FORM 8-K | 5.02,9.01 | 0001104659-21-088220 | 000-15006 | 211065814 | 34 | 790473 | ||
| 2021-06-21 | 4 | FORM 4 - | 0001179110-21-006912 | 5705 | ||||||
| 2021-06-21 | 4 | FORM 4 - | 0001179110-21-006911 | 5659 | ||||||
| 2021-06-21 | 4 | FORM 4 - | 0001179110-21-006910 | 5717 | ||||||
| 2021-06-21 | 4 | FORM 4 - | 0001179110-21-006909 | 5702 | ||||||
| 2021-06-21 | 4 | FORM 4 - | 0001179110-21-006908 | 5712 | ||||||
| 2021-06-21 | 4 | FORM 4 - | 0001179110-21-006907 | 5652 | ||||||
| 2021-06-21 | 4 | FORM 4 - | 0001179110-21-006906 | 5702 | ||||||
| 2021-06-21 | 4 | FORM 4 - | 0001179110-21-006905 | 5694 | ||||||
| 2021-06-21 | 4 | FORM 4 - | 0001179110-21-006904 | 5622 | ||||||
| 2021-06-21 | 4 | FORM 4 - | 0001179110-21-006903 | 5645 | ||||||
| 2021-06-21 | 4 | FORM 4 - | 0001179110-21-006892 | 5496 | ||||||
| 2021-06-21 | 4 | FORM 4 - | 0001179110-21-006890 | 5482 | ||||||
| 2021-06-21 | 4 | FORM 4 - | 0001179110-21-006889 | 5525 | ||||||
| 2021-06-21 | 4 | FORM 4 - | 0001179110-21-006888 | 5488 | ||||||
| 2021-06-21 | 4 | FORM 4 - | 0001179110-21-006887 | 5480 | ||||||
| 2021-06-17 | 8-K | FORM 8-K | 5.02,5.07,9.01 | 0001104659-21-082585 | 000-15006 | 211024664 | 34 | 327913 | ||
| 2021-06-16 | S-8 | FORM S-8 | 0001104659-21-081982 | 333-257137 | 211021441 | 33 | 79547 | |||
| 2021-05-06 | 10-Q | FORM 10-Q | 0001104659-21-062387 | 000-15006 | 21897700 | 34 | 4424435 | 1 | ||
| 2021-05-06 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-21-003256 | 000-15006 | 21897570 | 34 | 68977 | ||
| 2021-04-27 | DEF 14A | DEF 14A | 0001104659-21-055589 | 000-15006 | 21858925 | 34 | 2233358 | |||
| 2021-03-29 | 10-K | 10-K | 0001104659-21-043161 | 000-15006 | 21781764 | 34 | 8284947 | 1 | ||
| 2021-03-29 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-21-002135 | 000-15006 | 21781679 | 34 | 96296 | ||
| 2021-02-25 | SC 13G | COWEN FINANCIAL PRODUCTS LLC | 0001085146-21-001052 | 005-37761 | 21680022 | 34 | 27384 | |||
| 2021-02-16 | SC 13G | SC 13G | 0001104659-21-023928 | 005-37761 | 21638189 | 34 | 79351 | |||
| 2021-02-12 | SC 13G/A | SC 13G/A | 0001193125-21-041686 | 005-37761 | 21628261 | 34 | 118493 | |||
| 2021-02-12 | SC 13G/A | formsc13ga.htm | 0001493152-21-003530 | 005-37761 | 21623552 | 34 | 177318 | |||
| 2021-02-11 | SC 13G/A | AMENDMENT NO. 1 TO THE SCHEDULE 13G | 0000921895-21-000324 | 005-37761 | 21620233 | 34 | 269162 | |||
| 2021-02-11 | SC 13G/A | CELLDEX THERAPEUTICS, INC. | 0000902664-21-001119 | 005-37761 | 21616743 | 34 | 107745 | |||
| 2021-02-10 | SC 13G/A | cldx-13g_20201231.txt | 0001037389-21-000083 | 005-37761 | 21614728 | 34 | 13562 | |||
| 2021-01-04 | 3 | OWNERSHIP DOCUMENT | 0001104659-21-000105 | 17136 | ||||||
| 2021-01-04 | 8-K | FORM 8-K | 5.02,7.01,9.01 | 0001104659-21-000104 | 000-15006 | 21500233 | 34 | 112442 | ||
| 2020-12-16 | 4 | FORM 4 - | 0001179110-20-011996 | 13877 | ||||||
| 2020-11-06 | 8-K | FORM 8-K | 8.01,9.01 | 0001104659-20-122521 | 000-15006 | 201294719 | 34 | 20794 | ||
| 2020-11-06 | S-3ASR | S-3ASR | 0001104659-20-122483 | 333-249917 | 201294350 | 33 | 790358 | |||
| 2020-11-05 | 10-Q | FORM 10-Q | 0001104659-20-121786 | 000-15006 | 201290437 | 34 | 5272902 | 1 | ||
| 2020-11-05 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-20-007664 | 000-15006 | 201290300 | 34 | 91179 | ||
| 2020-10-22 | SC 13G | cldx13g.htm | 0000935836-20-000571 | 005-37761 | 201252959 | 34 | 60299 | |||
| 2020-08-18 | 8-K | FORM 8-K | 8.01 | 0001104659-20-096505 | 000-15006 | 201113587 | 34 | 19024 | ||
| 2020-08-06 | 10-Q | FORM 10-Q | 0001104659-20-091459 | 000-15006 | 201082014 | 34 | 4879690 | 1 | ||
| 2020-08-06 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-20-005651 | 000-15006 | 201081439 | 34 | 90389 | ||
| 2020-07-24 | SC 13G | CELLDEX THERAPEUTICS, INC. | 0000902664-20-002780 | 005-37761 | 201047008 | 34 | 108773 | |||
| 2020-06-26 | SC 13G | THE SCHEDULE 13G | 0000921895-20-001867 | 005-37761 | 20995235 | 34 | 290534 | |||
| 2020-06-26 | S-8 | S-8 | 0001104659-20-077437 | 333-239463 | 20994059 | 33 | 53155 | |||
| 2020-06-19 | SC 13G | sc13g.htm | 0001493152-20-011453 | 005-37761 | 20974581 | 34 | 173220 | |||
| 2020-06-19 | 4 | FORM 4 - | 0001179110-20-007598 | 5698 | ||||||
| 2020-06-19 | 4 | FORM 4 - | 0001179110-20-007597 | 5712 | ||||||
| 2020-06-19 | 4 | FORM 4 - | 0001179110-20-007596 | 5713 | ||||||
| 2020-06-19 | 4 | FORM 4 - | 0001179110-20-007595 | 5703 | ||||||
| 2020-06-19 | 4 | FORM 4 - | 0001179110-20-007594 | 5653 | ||||||
| 2020-06-19 | 4 | FORM 4 - | 0001179110-20-007593 | 5703 | ||||||
| 2020-06-19 | 4 | FORM 4 - | 0001179110-20-007592 | 5660 | ||||||
| 2020-06-19 | 4 | FORM 4 - | 0001179110-20-007591 | 5626 | ||||||
| 2020-06-19 | 4 | FORM 4 - | 0001179110-20-007590 | 5646 | ||||||
| 2020-06-19 | 4 | FORM 4 - | 0001179110-20-007589 | 5459 | ||||||
| 2020-06-19 | 4 | FORM 4 - | 0001179110-20-007588 | 5481 | ||||||
| 2020-06-19 | 4 | FORM 4 - | 0001179110-20-007587 | 5489 | ||||||
| 2020-06-19 | 4 | FORM 4 - | 0001179110-20-007586 | 5526 | ||||||
| 2020-06-19 | 4 | FORM 4 - | 0001179110-20-007585 | 5483 | ||||||
| 2020-06-18 | 8-K | FORM 8-K | 5.02,5.07,9.01 | 0001104659-20-074646 | 000-15006 | 20972520 | 34 | 153446 | ||
| 2020-06-18 | SC 13G | SC 13G | 0001193125-20-171962 | 005-37761 | 20971348 | 34 | 115271 | |||
| 2020-06-17 | 424B5 | 424B5 | 0001047469-20-003646 | 333-235399 | 20967970 | 33 | 322108 | |||
| 2020-06-17 | 8-K | FORM 8-K | 1.01,8.01,9.01 | 0001104659-20-073843 | 000-15006 | 20967435 | 34 | 348607 | ||
| 2020-06-15 | S-3MEF | S-3MEF | 0001104659-20-073505 | 333-239199 | 20964703 | 33 | 51047 | |||
| 2020-06-15 | 8-K | FORM 8-K | 8.01 | 0001104659-20-073386 | 000-15006 | 20963399 | 34 | 30069 | ||
| 2020-06-15 | 424B5 | 424B5 | 0001047469-20-003602 | 333-235399 | 20963395 | 33 | 317580 | |||
| 2020-06-15 | 424B5 | 424B5 | 0001047469-20-003601 | 333-235399 | 20963387 | 33 | 47403 | |||
| 2020-06-12 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2020-06-12 14:00:00 | 9999999995-20-001412 | 333-235399 | 20961810 | 33 | 1923 | ||
| 2020-06-12 | 8-K | FORM 8-K | 8.01,9.01 | 0001104659-20-072934 | 000-15006 | 20960533 | 34 | 31019 | ||
| 2020-06-12 | 424B5 | 424B5 | 0001047469-20-003564 | 333-235399 | 20960035 | 33 | 254663 | |||
| 2020-06-12 | CORRESP | filename1.htm | 0001104659-20-072779 | 8664 | ||||||
| 2020-06-12 | 4 | FORM 4 - | 0001179110-20-007242 | 4663 | ||||||
| 2020-06-12 | S-3/A | FORM S-3/A | 0001104659-20-072503 | 333-235399 | 20958224 | 33 | 221274 | |||
| 2020-06-11 | 4 | FORM 4 - | 0001179110-20-007218 | 4716 | ||||||
| 2020-06-10 | 4 | FORM 4 - | 0001179110-20-007167 | 4716 | ||||||
| 2020-06-10 | 4 | FORM 4 - | 0001179110-20-007166 | 4883 | ||||||
| 2020-06-10 | 4 | FORM 4 - | 0001179110-20-007165 | 4667 | ||||||
| 2020-06-10 | 4 | FORM 4 - | 0001179110-20-007164 | 4628 | ||||||
| 2020-06-10 | 4 | FORM 4 - | 0001179110-20-007163 | 4834 | ||||||
| 2020-05-06 | 10-Q | FORM 10-Q | 0001104659-20-057436 | 000-15006 | 20852811 | 34 | 4166545 | 1 | ||
| 2020-05-06 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-20-003372 | 000-15006 | 20852514 | 34 | 63791 | ||
| 2020-04-28 | DEF 14A | DEF 14A | 0001047469-20-002644 | 000-15006 | 20825071 | 34 | 1137179 | |||
| 2020-03-27 | 424B5 | 424B5 | 0001104659-20-039253 | 333-214882 | 20748076 | 33 | 20303 | |||
| 2020-03-26 | 10-K | 10-K | 0001047469-20-001809 | 000-15006 | 20746239 | 34 | 8045650 | 1 | ||
| 2020-03-26 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-20-002037 | 000-15006 | 20746124 | 34 | 94844 | ||
| 2020-02-12 | SC 13G | cldx-13g_20191231.txt | 0001037389-20-000083 | 005-37761 | 20603935 | 34 | 13529 | |||
| 2019-12-12 | UPLOAD | filename1.pdf | 0000000000-19-016322 | 46285 | ||||||
| 2019-12-06 | S-3 | S-3 | 0001047469-19-006714 | 333-235399 | 191273114 | 33 | 246571 | |||
| 2019-11-12 | 10-Q | 10-Q | 0001104659-19-062181 | 000-15006 | 191206476 | 34 | 5791161 | 1 | ||
| 2019-11-12 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-19-007429 | 000-15006 | 191206220 | 34 | 93897 | ||
| 2019-08-07 | 10-Q | 10-Q | 0001104659-19-044531 | 000-15006 | 191005483 | 34 | 5432994 | 1 | ||
| 2019-08-07 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-19-005251 | 000-15006 | 191005356 | 34 | 98813 | ||
| 2019-07-09 | 4 | FORM 4 - | 0001179110-19-008540 | 5653 | ||||||
| 2019-07-08 | 3 | 3 | 0001104659-19-039565 | 10387 | ||||||
| 2019-06-24 | 8-K | 8-K | 5.02,7.01,9.01 | 0001104659-19-037195 | 000-15006 | 19915256 | 34 | 136955 | ||
| 2019-06-21 | S-8 | S-8 | 0001104659-19-037010 | 333-232255 | 19911592 | 33 | 87882 | |||
| 2019-06-21 | S-8 | S-8 | 0001104659-19-036997 | 333-232253 | 19911519 | 33 | 88872 | |||
| 2019-06-20 | 4 | FORM 4 - | 0001179110-19-007979 | 5649 | ||||||
| 2019-06-20 | 4 | FORM 4 - | 0001179110-19-007978 | 5699 | ||||||
| 2019-06-20 | 4 | FORM 4 - | 0001179110-19-007977 | 5708 | ||||||
| 2019-06-20 | 4 | FORM 4 - | 0001179110-19-007976 | 5699 | ||||||
| 2019-06-20 | 4 | FORM 4 - | 0001179110-19-007975 | 5709 | ||||||
| 2019-06-20 | 4 | FORM 4 - | 0001179110-19-007974 | 5691 |
One latest value per concept from companyfacts (303 concepts). Full history stays in the JSON.
| Taxonomy | Tag | Label | Unit | Value | Start | End | FY | FP | Form | Filed | Accn |
|---|---|---|---|---|---|---|---|---|---|---|---|
| dei | EntityCommonStockSharesOutstanding | Entity Common Stock, Shares Outstanding | shares | 78.55M | 2026-10-28 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| dei | EntityPublicFloat | Entity Public Float | USD | 1.30B | 2025-06-30 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 | |
| ecd | CoSelectedMeasureAmt | CoSelectedMeasureAmt | USD | 518.57M | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-29 | 0001104659-26-050884 | ||
| ecd | NonPeoNeoAvgCompActuallyPaidAmt | NonPeoNeoAvgCompActuallyPaidAmt | USD | 1.73M | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-29 | 0001104659-26-050884 | ||
| ecd | NonPeoNeoAvgTotalCompAmt | NonPeoNeoAvgTotalCompAmt | USD | 1.91M | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-29 | 0001104659-26-050884 | ||
| ecd | PeerGroupTotalShareholderRtnAmt | PeerGroupTotalShareholderRtnAmt | USD | 201 | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-29 | 0001104659-26-050884 | ||
| ecd | PeoActuallyPaidCompAmt | PeoActuallyPaidCompAmt | USD | 4.83M | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-29 | 0001104659-26-050884 | ||
| ecd | PeoTotalCompAmt | PeoTotalCompAmt | USD | 5.37M | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-29 | 0001104659-26-050884 | ||
| ecd | TotalShareholderRtnAmt | TotalShareholderRtnAmt | USD | 155 | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-29 | 0001104659-26-050884 | ||
| ffd | NetFeeAmt | NetFeeAmt | USD | 0 | 2026-10-29 | S-3ASR | 2026-11-05 | 0001104659-26-123391 | |||
| ffd | TtlFeeAmt | TtlFeeAmt | USD | 0 | 2026-10-29 | S-3ASR | 2026-11-05 | 0001104659-26-123391 | |||
| ffd | TtlOfferingAmt | TtlOfferingAmt | USD | 0 | 2026-10-29 | S-3ASR | 2026-11-05 | 0001104659-26-123391 | |||
| ffd | TtlOffsetAmt | TtlOffsetAmt | USD | 0 | 2026-10-29 | S-3ASR | 2026-11-05 | 0001104659-26-123391 | |||
| ffd | TtlPrevslyPdAmt | TtlPrevslyPdAmt | USD | 0 | 2026-10-29 | S-3ASR | 2026-11-05 | 0001104659-26-123391 | |||
| us-gaap | AccountsAndOtherReceivablesNetCurrent | Accounts and Other Receivables, Net, Current | USD | 355,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | AccountsPayableCurrent | Accounts Payable, Current | USD | 11.24M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | AccretionAmortizationOfDiscountsAndPremiumsInvestments | Accretion (Amortization) of Discounts and Premiums, Investments | USD | 3.12M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | AccruedLiabilitiesCurrent | Accrued Liabilities, Current | USD | 46.61M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | AccruedProfessionalFeesCurrent | Accrued Professional Fees, Current | USD | 1.48M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 | |
| us-gaap | AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment | Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | USD | 23.90M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 | |
| us-gaap | AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax | Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax | USD | 2.60M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 | |
| us-gaap | AccumulatedOtherComprehensiveIncomeLossNetOfTax | Accumulated Other Comprehensive Income (Loss), Net of Tax | USD | -329,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | AdditionalPaidInCapitalCommonStock | Additional Paid in Capital, Common Stock | USD | 2.69B | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue | APIC, Share-based Payment Arrangement, Increase for Cost Recognition | USD | 10.97M | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | AllocatedShareBasedCompensationExpense | Share-based Payment Arrangement, Expense | USD | 27.91M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | AmortizationOfDebtDiscountPremium | Amortization of Debt Discount (Premium) | USD | 1.64M | 2016-01-01 | 2016-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001047469-19-000992 |
| us-gaap | AmortizationOfIntangibleAssets | Amortization of Intangible Assets | USD | 0 | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-29 | 0001104659-21-043161 |
| us-gaap | AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares | 11.58M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | AreaOfRealEstateProperty | Area of Real Estate Property | sqft | 33,000 | 2013-05-02 | 2013 | Q3 | 10-Q | 2013-11-08 | 0001104659-13-082619 | |
| us-gaap | AssetImpairmentCharges | Asset Impairment Charges | USD | 18.68M | 2018-01-01 | 2018-03-31 | 2019 | Q1 | 10-Q | 2019-05-07 | 0001104659-19-027513 |
| us-gaap | Assets | Assets | USD | 721.53M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | AssetsCurrent | Assets, Current | USD | 663.74M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | USD | 7,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | USD | 2.93M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | AvailableForSaleDebtSecuritiesAmortizedCostBasis | Debt Securities, Available-for-sale, Amortized Cost | USD | 626.29M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax | Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax | USD | 5,000 | 2021-06-30 | 2021 | Q2 | 10-Q | 2021-08-05 | 0001104659-21-100745 | |
| us-gaap | AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax | Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax | USD | 9,000 | 2021-06-30 | 2021 | Q2 | 10-Q | 2021-08-05 | 0001104659-21-100745 | |
| us-gaap | AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost | Available-for-sale Securities, Debt Maturities, Amortized Cost Basis (Deprecated 2014-01-31) | USD | 211.41M | 2014-06-30 | 2014 | Q2 | 10-Q | 2014-08-07 | 0001104659-14-057922 | |
| us-gaap | AvailableForSaleSecuritiesDebtSecuritiesCurrent | Debt Securities, Available-for-sale, Current | USD | 53.53M | 2019-03-31 | 2019 | Q1 | 10-Q | 2019-05-07 | 0001104659-19-027513 | |
| us-gaap | AvailableforsaleSecuritiesGrossUnrealizedGain | Available-for-sale Securities, Gross Unrealized Gains (Deprecated 2013-01-31) | USD | 86,000 | 2013-06-30 | 2013 | Q2 | 10-Q | 2013-08-06 | 0001104659-13-060226 | |
| us-gaap | AvailableForSaleSecuritiesGrossUnrealizedLosses1 | Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31) | USD | 124,000 | 2013-06-30 | 2013 | Q2 | 10-Q | 2013-08-06 | 0001104659-13-060226 | |
| us-gaap | BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued | Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | shares | 1.22M | 2016-11-29 | 2021 | Q1 | 10-Q | 2021-05-06 | 0001104659-21-062387 | |
| us-gaap | BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount | Business Acquisition, Goodwill, Expected Tax Deductible Amount | USD | 0 | 2016-11-29 | 2018 | FY | 10-K | 2019-03-07 | 0001047469-19-000992 | |
| us-gaap | BusinessCombinationAcquisitionRelatedCosts | Business Combination, Acquisition Related Costs | USD | 700,000 | 2016-01-01 | 2016-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001047469-19-000992 |
| us-gaap | BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1 | Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 | Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability | USD | -29.62M | 2018-01-01 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001047469-19-000992 |
| us-gaap | BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh | Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | USD | 107.50M | 2021-03-31 | 2021 | Q1 | 10-Q | 2021-05-06 | 0001104659-21-062387 | |
| us-gaap | BusinessCombinationContingentConsiderationLiability | Business Combination, Contingent Consideration, Liability | USD | 6.86M | 2021-12-31 | 2022 | FY | 10-K | 2023-02-28 | 0001104659-23-026701 | |
| us-gaap | BusinessCombinationContingentConsiderationLiabilityMeasurementInput | Business Combination, Contingent Consideration, Liability, Measurement Input | Y | 4 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-29 | 0001104659-21-043161 | |
| us-gaap | CapitalExpendituresIncurredButNotYetPaid | Capital Expenditures Incurred but Not yet Paid | USD | 75,000 | 2017-01-01 | 2017-09-30 | 2017 | Q3 | 10-Q | 2017-11-07 | 0001104659-17-066472 |
| us-gaap | CashAcquiredFromAcquisition | Cash Acquired from Acquisition | USD | 4.59M | 2016-01-01 | 2016-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001047469-19-000992 |
| us-gaap | CashAndCashEquivalentsAtCarryingValue | Cash and Cash Equivalents, at Carrying Value | USD | 26.95M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | CashAndCashEquivalentsPeriodIncreaseDecrease | Cash and Cash Equivalents, Period Increase (Decrease) | USD | -13.08M | 2019-01-01 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-26 | 0001047469-20-001809 |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | USD | 26.95M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | USD | -1.92M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | CommonStockParOrStatedValuePerShare | Common Stock, Par or Stated Value Per Share | USD/shares | 0.001 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | CommonStockSharesAuthorized | Common Stock, Shares Authorized | shares | 297.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | CommonStockSharesIssued | Common Stock, Shares, Issued | shares | 78.53M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | CommonStockSharesOutstanding | Common Stock, Shares, Outstanding | shares | 78.53M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | CommonStockValue | Common Stock, Value, Issued | USD | 79,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | ComprehensiveIncomeNetOfTax | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | USD | -231.70M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | ConstructionInProgressExpendituresIncurredButNotYetPaid | Construction in Progress Expenditures Incurred but Not yet Paid | USD | 711,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | ContractWithCustomerAssetNet | Contract with Customer, Asset, after Allowance for Credit Loss | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | ContractWithCustomerLiability | Contract with Customer, Liability | USD | 1.80M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | ContractWithCustomerLiabilityRevenueRecognized | Contract with Customer, Liability, Revenue Recognized | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | ConvertibleSubordinatedDebtCurrent | Convertible Subordinated Debt, Current | USD | 12.41M | 2010-12-31 | 2011 | FY | 10-K | 2012-03-08 | 0001047469-12-002276 | |
| us-gaap | CostMethodInvestmentsOriginalCost | Cost Method Investments, Original Cost | USD | 1.80M | 2018-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001047469-19-000992 | |
| us-gaap | CostOfGoodsAndServicesSold | Cost of Goods and Services Sold | USD | 200,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 |
| us-gaap | CostsAndExpenses | Costs and Expenses | USD | 247.35M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | DebtInstrumentInterestRateAtPeriodEnd | Debt Instrument, Interest Rate at Period End (Deprecated 2014-01-31) | pure | 0.055 | 2012-12-31 | 2012 | FY | 10-K | 2013-03-08 | 0001047469-13-002403 | |
| us-gaap | DeferredIncomeTaxExpenseBenefit | Deferred Income Tax Expense (Benefit) | USD | -5.20M | 2017-01-01 | 2017-09-30 | 2017 | Q3 | 10-Q | 2017-11-07 | 0001104659-17-066472 |
| us-gaap | DeferredIncomeTaxLiabilities | Deferred Tax Liabilities, Gross | USD | 30.92M | 2016-12-31 | 2016 | FY | 10-K | 2017-03-14 | 0001047469-17-001564 | |
| us-gaap | DeferredIncomeTaxLiabilitiesNet | Deferred Income Tax Liabilities, Net | USD | 4.66M | 2016-06-30 | 2016 | Q2 | 10-Q | 2016-08-08 | 0001104659-16-137913 | |
| us-gaap | DeferredRentCredit | Deferred Rent Credit | USD | 669,000 | 2017-09-30 | 2017 | Q3 | 10-Q | 2017-11-07 | 0001104659-17-066472 | |
| us-gaap | DeferredRevenue | Deferred Revenue | USD | 2.08M | 2018-09-30 | 2018 | Q3 | 10-Q | 2018-11-07 | 0001104659-18-066648 | |
| us-gaap | DeferredTaxAssetsDeferredIncome | Deferred Tax Assets, Deferred Income | USD | 13,000 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001047469-19-000992 | |
| us-gaap | DeferredTaxAssetsGross | Deferred Tax Assets, Gross | USD | 380.40M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 | |
| us-gaap | DeferredTaxAssetsOperatingLossCarryforwards | Deferred Tax Assets, Operating Loss Carryforwards | USD | 245.76M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 | |
| us-gaap | DeferredTaxAssetsOperatingLossCarryforwardsForeign | Deferred Tax Assets, Operating Loss Carryforwards, Foreign | USD | 4.49M | 2018-12-31 | 2019 | FY | 10-K | 2020-03-26 | 0001047469-20-001809 | |
| us-gaap | DeferredTaxAssetsPropertyPlantAndEquipment | Deferred Tax Assets, Property, Plant and Equipment | USD | 392,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 | |
| us-gaap | DeferredTaxAssetsTaxCreditCarryforwards | Deferred Tax Assets, Tax Credit Carryforwards | USD | 37.52M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpense | Deferred Tax Assets, Tax Deferred Expense | USD | 86.25M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | USD | 8.86M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseOther | Deferred Tax Assets, Tax Deferred Expense, Other | USD | 1.62M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 | |
| us-gaap | DeferredTaxAssetsValuationAllowance | Deferred Tax Assets, Valuation Allowance | USD | 374.50M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 | |
| us-gaap | DeferredTaxLiabilities | Deferred Tax Liabilities, Net | USD | 1.61M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | DeferredTaxLiabilitiesOther | Deferred Tax Liabilities, Other | USD | 670,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 | |
| us-gaap | DefinedContributionPlanCostRecognized | Defined Contribution Plan, Cost | USD | 600,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 |
| us-gaap | DefinedContributionPlanEmployerMatchingContributionPercent | Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay | pure | 0.04 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 |
| us-gaap | DefinedContributionPlanEmployerMatchingContributionPercentOfMatch | Defined Contribution Plan, Employer Matching Contribution, Percent of Match | pure | 0.5 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 |
| us-gaap | DefinedContributionPlanMaximumAnnualContributionPerEmployeePercent | Defined Contribution Plan, Maximum Annual Contribution Per Employee, Percent (Deprecated 2013-01-31) | pure | 0.04 | 2012-01-01 | 2012-12-31 | 2012 | FY | 10-K | 2013-03-08 | 0001047469-13-002403 |
| us-gaap | DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent | Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent | pure | 0.6 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 |
| us-gaap | DepreciationDepletionAndAmortization | Depreciation, Depletion and Amortization | USD | 2.92M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | Dividends | Dividends | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 |
| us-gaap | EarningsPerShareBasic | Earnings Per Share, Basic | USD/shares | -3.06 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | EarningsPerShareBasicAndDiluted | Earnings Per Share, Basic and Diluted | USD/shares | -1.21 | 2021-01-01 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-09 | 0001104659-21-136268 |
| us-gaap | EarningsPerShareDiluted | Earnings Per Share, Diluted | USD/shares | -3.06 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | EffectiveIncomeTaxRateContinuingOperations | Effective Income Tax Rate Reconciliation, Percent | pure | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 |
| us-gaap | EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | pure | 0.21 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 |
| us-gaap | EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent | pure | -0.189 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent | pure | -0.009 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent | pure | -0.057 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 |
| us-gaap | EffectiveIncomeTaxRateReconciliationOtherAdjustments | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent | pure | -0.001 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxCreditsResearch | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent | pure | -0.046 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 |
| us-gaap | EffectOfExchangeRateOnCashAndCashEquivalents | Effect of Exchange Rate on Cash and Cash Equivalents | USD | -5,000 | 2011-01-01 | 2011-06-30 | 2011 | Q2 | 10-Q | 2011-08-04 | 0001104659-11-043630 |
| us-gaap | EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations | Effect of Exchange Rate on Cash and Cash Equivalents, Continuing Operations | USD | 15,000 | 2015-01-01 | 2015-12-31 | 2017 | FY | 10-K | 2018-03-07 | 0001047469-18-001363 |
| us-gaap | EmployeeRelatedLiabilitiesCurrent | Employee-related Liabilities, Current | USD | 11.81M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 | |
| us-gaap | EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | USD | 85.40M | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-06 | 0001410578-24-001766 | |
| us-gaap | EquitySecuritiesFvNiCost | Equity Securities, FV-NI, Cost | USD | 1.80M | 2018-12-31 | 2021 | FY | 10-K | 2022-02-28 | 0001104659-22-028070 | |
| us-gaap | EquitySecuritiesWithoutReadilyDeterminableFairValueAmount | Equity Securities without Readily Determinable Fair Value, Amount | USD | 1.80M | 2016-12-31 | 2020 | Q3 | 10-Q | 2020-11-05 | 0001104659-20-121786 | |
| us-gaap | FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3 | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3 | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3 | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3 | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | FederalIncomeTaxExpenseBenefitContinuingOperations | Federal Income Tax Expense (Benefit), Continuing Operations | USD | -48.97M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 |
| us-gaap | FiniteLivedIntangibleAssetsAccumulatedAmortization | Finite-Lived Intangible Assets, Accumulated Amortization | USD | 7.62M | 2018-09-30 | 2018 | Q3 | 10-Q | 2018-11-07 | 0001104659-18-066648 | |
| us-gaap | FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths | Finite-Lived Intangible Asset, Expected Amortization, Year One | USD | 900,000 | 2017-12-31 | 2017 | FY | 10-K | 2018-03-07 | 0001047469-18-001363 | |
| us-gaap | FiniteLivedIntangibleAssetsAmortizationExpenseYearFive | Finite-Lived Intangible Asset, Expected Amortization, Year Five | USD | 900,000 | 2017-12-31 | 2017 | FY | 10-K | 2018-03-07 | 0001047469-18-001363 | |
| us-gaap | FiniteLivedIntangibleAssetsAmortizationExpenseYearFour | Finite-Lived Intangible Asset, Expected Amortization, Year Four | USD | 900,000 | 2017-12-31 | 2017 | FY | 10-K | 2018-03-07 | 0001047469-18-001363 | |
| us-gaap | FiniteLivedIntangibleAssetsAmortizationExpenseYearThree | Finite-Lived Intangible Asset, Expected Amortization, Year Three | USD | 900,000 | 2017-12-31 | 2017 | FY | 10-K | 2018-03-07 | 0001047469-18-001363 | |
| us-gaap | FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo | Finite-Lived Intangible Asset, Expected Amortization, Year Two | USD | 900,000 | 2017-12-31 | 2017 | FY | 10-K | 2018-03-07 | 0001047469-18-001363 | |
| us-gaap | FiniteLivedIntangibleAssetsNet | Finite-Lived Intangible Assets, Net | USD | 0 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001047469-19-000992 | |
| us-gaap | ForeignIncomeTaxExpenseBenefitContinuingOperations | Foreign Income Tax Expense (Benefit), Continuing Operations | USD | -913,000 | 2018-01-01 | 2018-12-31 | 2020 | FY | 10-K | 2021-03-29 | 0001104659-21-043161 |
| us-gaap | GainLossOnDispositionOfAssets | Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property | USD | 50,000 | 2011-01-01 | 2011-12-31 | 2011 | FY | 10-K | 2012-03-08 | 0001047469-12-002276 |
| us-gaap | GainLossOnSaleOfOtherAssets | Gain (Loss) on Disposition of Other Assets | USD | 500,000 | 2017-01-01 | 2017-06-30 | 2017 | Q2 | 10-Q | 2017-08-08 | 0001104659-17-050250 |
| us-gaap | GainLossOnSaleOfPropertyPlantEquipment | Gain (Loss) on Disposition of Property Plant Equipment | USD | -51,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | GainLossRelatedToLitigationSettlement | Gain (Loss) Related to Litigation Settlement | USD | -12.50M | 2023-01-01 | 2023-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 |
| us-gaap | GeneralAndAdministrativeExpense | General and Administrative Expense | USD | 39.40M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | Goodwill | Goodwill | USD | 90.98M | 2017-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001047469-19-000992 | |
| us-gaap | GoodwillImpairmentLoss | Goodwill, Impairment Loss | USD | 90.98M | 2018-01-01 | 2018-12-31 | 2020 | FY | 10-K | 2021-03-29 | 0001104659-21-043161 |
| us-gaap | ImpairmentOfIntangibleAssetsFinitelived | Impairment of Intangible Assets, Finite-lived | USD | 3.50M | 2021-07-01 | 2021-09-30 | 2021 | FY | 10-K | 2022-02-28 | 0001104659-22-028070 |
| us-gaap | ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) | USD | 3.50M | 2021-01-01 | 2021-12-31 | 2023 | FY | 10-K | 2024-02-26 | 0001410578-24-000076 |
| us-gaap | ImpairmentOfInvestments | Other than Temporary Impairment Losses, Investments | USD | 1.80M | 2019-01-01 | 2019-03-31 | 2021 | FY | 10-K | 2022-02-28 | 0001104659-22-028070 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | USD | -258.76M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign | Income (Loss) from Continuing Operations before Income Taxes, Foreign | USD | 0 | 2022-01-01 | 2022-12-31 | 2023 | FY | 10-K | 2024-02-26 | 0001410578-24-000076 |
| us-gaap | IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | USD | -37.88M | 2020-01-01 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-05 | 0001104659-20-121786 |
| us-gaap | IncomeTaxesPaidNet | Income Taxes Paid, Net | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 |
| us-gaap | IncomeTaxExpenseBenefit | Income Tax Expense (Benefit) | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 |
| us-gaap | IncomeTaxExpenseBenefitContinuingOperations | Income Tax Expense (Benefit), Continuing Operations (Deprecated 2013-01-31) | USD | -22.20M | 2012-01-01 | 2012-12-31 | 2012 | FY | 10-K | 2013-03-08 | 0001047469-13-002403 |
| us-gaap | IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount | USD | 48.97M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 |
| us-gaap | IncomeTaxReconciliationChangeInEnactedTaxRate | Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount | USD | 99.53M | 2017-01-01 | 2017-12-31 | 2019 | FY | 10-K | 2020-03-26 | 0001047469-20-001809 |
| us-gaap | IncomeTaxReconciliationForeignIncomeTaxRateDifferential | Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount | USD | 326,000 | 2017-01-01 | 2017-12-31 | 2019 | FY | 10-K | 2020-03-26 | 0001047469-20-001809 |
| us-gaap | IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount | USD | -54.34M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 |
| us-gaap | IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount | USD | 19.11M | 2018-01-01 | 2018-12-31 | 2020 | FY | 10-K | 2021-03-29 | 0001104659-21-043161 |
| us-gaap | IncomeTaxReconciliationNondeductibleExpenseOther | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount | USD | 2.18M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 |
| us-gaap | IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount | USD | 14.70M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 |
| us-gaap | IncomeTaxReconciliationOtherAdjustments | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount | USD | 294,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 |
| us-gaap | IncomeTaxReconciliationStateAndLocalIncomeTaxes | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount | USD | -15.38M | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 |
| us-gaap | IncomeTaxReconciliationTaxContingenciesOther | Effective Income Tax Rate Reconciliation, Tax Contingency, Other, Amount | USD | -1.44M | 2022-01-01 | 2022-12-31 | 2024 | FY | 10-K | 2025-02-27 | 0001410578-25-000216 |
| us-gaap | IncomeTaxReconciliationTaxCreditsResearch | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount | USD | 11.81M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 |
| us-gaap | IncreaseDecreaseInAccountsAndOtherReceivables | Increase (Decrease) in Accounts and Other Receivables | USD | -1.66M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | IncreaseDecreaseInAccountsPayableAndAccruedLiabilities | Increase (Decrease) in Accounts Payable and Accrued Liabilities | USD | 9.03M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | IncreaseDecreaseInDeferredRevenue | Increase (Decrease) in Deferred Revenue | USD | -39.38M | 2010-01-01 | 2010-12-31 | 2012 | FY | 10-K | 2013-03-08 | 0001047469-13-002403 |
| us-gaap | IncreaseDecreaseInEquitySecuritiesFvNi | Increase (Decrease) in Equity Securities, FV-NI | USD | 0 | 2020-01-01 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-05 | 0001104659-20-121786 |
| us-gaap | IncreaseDecreaseInOtherOperatingAssets | Increase (Decrease) in Other Operating Assets | USD | -3.67M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | IncreaseDecreaseInOtherOperatingLiabilities | Increase (Decrease) in Other Operating Liabilities | USD | -2.42M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets | Increase (Decrease) in Prepaid Expense and Other Assets | USD | -11,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | IndefiniteLivedIntangibleAssetsExcludingGoodwill | Indefinite-lived Intangible Assets (Excluding Goodwill) | USD | 27.20M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | IntangibleAssetsGrossExcludingGoodwill | Intangible Assets, Gross (Excluding Goodwill) | USD | 74.99M | 2018-09-30 | 2018 | Q3 | 10-Q | 2018-11-07 | 0001104659-18-066648 | |
| us-gaap | IntangibleAssetsNetExcludingGoodwill | Intangible Assets, Net (Excluding Goodwill) | USD | 27.19M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | InterestAndOtherIncome | Interest and Other Income | USD | 19.56M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | InterestExpense | Interest Expense | USD | 927,000 | 2013-01-01 | 2013-12-31 | 2015 | FY | 10-K/A | 2016-02-25 | 0001047469-16-010396 |
| us-gaap | InterestPaid | Interest Paid, Including Capitalized Interest, Operating and Investing Activities | USD | 1.21M | 2013-01-01 | 2013-12-31 | 2015 | FY | 10-K/A | 2016-02-25 | 0001047469-16-010396 |
| us-gaap | InterestReceivable | Interest Receivable | USD | 5.50M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | InvestmentsAndCash | Investments and Cash | USD | 650.30M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDue | Lessee, Operating Lease, Liability, to be Paid | USD | 2.51M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths | Lessee, Operating Lease, Liability, to be Paid, Year One | USD | 1.71M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearFive | Lessee, Operating Lease, Liability, to be Paid, Year Five | USD | 311,000 | 2019-09-30 | 2019 | Q3 | 10-Q | 2019-11-12 | 0001104659-19-062181 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearFour | Lessee, Operating Lease, Liability, to be Paid, Year Four | USD | 311,000 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-26 | 0001047469-20-001809 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearThree | Lessee, Operating Lease, Liability, to be Paid, Year Three | USD | 742,000 | 2024-12-31 | 2024 | FY | 10-K | 2025-02-27 | 0001410578-25-000216 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearTwo | Lessee, Operating Lease, Liability, to be Paid, Year Two | USD | 804,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear | Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year | USD | 524,000 | 2019-09-30 | 2019 | Q3 | 10-Q | 2019-11-12 | 0001104659-19-062181 | |
| us-gaap | LesseeOperatingLeaseLiabilityUndiscountedExcessAmount | Lessee, Operating Lease, Liability, Undiscounted Excess Amount | USD | 173,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 | |
| us-gaap | Liabilities | Liabilities | USD | 72.06M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | LiabilitiesAndStockholdersEquity | Liabilities and Equity | USD | 721.53M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | LiabilitiesCurrent | Liabilities, Current | USD | 60.52M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | LiabilityForUncertainTaxPositionsCurrent | Liability for Uncertainty in Income Taxes, Current | USD | 0 | 2016-12-31 | 2016 | FY | 10-K | 2017-03-14 | 0001047469-17-001564 | |
| us-gaap | LicenseCosts | License Costs (Deprecated 2018-01-31) | USD | 700,000 | 2017-01-01 | 2017-12-31 | 2017 | FY | 10-K | 2018-03-07 | 0001047469-18-001363 |
| us-gaap | LitigationSettlementExpense | Litigation Settlement, Expense | USD | 15.00M | 2022-01-01 | 2022-06-30 | 2022 | Q2 | 10-Q | 2022-08-08 | 0001104659-22-087222 |
| us-gaap | LoansPayable | Loans Payable | USD | 472,000 | 2012-12-31 | 2013 | FY | 10-K | 2014-03-03 | 0001047469-14-001653 | |
| us-gaap | MarketableSecuritiesCurrent | Marketable Securities, Current | USD | 623.37M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | MarketableSecuritiesGainLoss | Marketable Securities, Gain (Loss) | USD | 11,000 | 2014-01-01 | 2014-12-31 | 2016 | FY | 10-K | 2017-03-14 | 0001047469-17-001564 |
| us-gaap | MarketableSecuritiesUnrealizedGainLoss | Marketable Securities, Unrealized Gain (Loss) | USD | -576.50M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | NetCashProvidedByUsedInContinuingOperations | Net Cash Provided by (Used in) Continuing Operations | USD | 94.15M | 2015-01-01 | 2015-03-31 | 2015 | Q1 | 10-Q | 2015-04-29 | 0001104659-15-031298 |
| us-gaap | NetCashProvidedByUsedInFinancingActivities | Net Cash Provided by (Used in) Financing Activities | USD | 326.10M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | NetCashProvidedByUsedInFinancingActivitiesContinuingOperations | Net Cash Provided by (Used in) Financing Activities, Continuing Operations | USD | 12.90M | 2017-01-01 | 2017-03-31 | 2017 | Q1 | 10-Q | 2017-05-09 | 0001104659-17-031139 |
| us-gaap | NetCashProvidedByUsedInInvestingActivities | Net Cash Provided by (Used in) Investing Activities | USD | -139.99M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | NetCashProvidedByUsedInInvestingActivitiesContinuingOperations | Net Cash Provided by (Used in) Investing Activities, Continuing Operations | USD | 22.40M | 2017-01-01 | 2017-03-31 | 2017 | Q1 | 10-Q | 2017-05-09 | 0001104659-17-031139 |
| us-gaap | NetCashProvidedByUsedInOperatingActivities | Net Cash Provided by (Used in) Operating Activities | USD | -188.03M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | NetCashProvidedByUsedInOperatingActivitiesContinuingOperations | Net Cash Provided by (Used in) Operating Activities, Continuing Operations | USD | -35.26M | 2017-01-01 | 2017-03-31 | 2017 | Q1 | 10-Q | 2017-05-09 | 0001104659-17-031139 |
| us-gaap | NetIncomeLoss | Net Income (Loss) Attributable to Parent | USD | -227.75M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | NetIncomeLossAvailableToCommonStockholdersBasic | Net Income (Loss) Available to Common Stockholders, Basic | USD | -227.75M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | NonoperatingIncomeExpense | Nonoperating Income (Expense) | USD | 436,000 | 2012-01-01 | 2012-09-30 | 2012 | Q3 | 10-Q | 2012-11-02 | 0001104659-12-073441 |
| us-gaap | NumberOfOperatingSegments | Number of Operating Segments | segment | 1 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | NumberOfReportableSegments | Number of Reportable Segments | segment | 1 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | NumberOfStatesInWhichEntityOperates | Number of States in which Entity Operates | state | 3 | 2017-09-30 | 2017 | Q3 | 10-Q | 2017-11-07 | 0001104659-17-066472 | |
| us-gaap | OperatingIncomeLoss | Operating Income (Loss) | USD | -247.31M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | OperatingLeaseCost | Operating Lease, Cost | USD | 2.10M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 |
| us-gaap | OperatingLeaseExpense | Operating Lease, Expense | USD | 4.00M | 2018-01-01 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001047469-19-000992 |
| us-gaap | OperatingLeaseLiability | Operating Lease, Liability | USD | 2.34M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 | |
| us-gaap | OperatingLeaseLiabilityCurrent | Operating Lease, Liability, Current | USD | 1.44M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | OperatingLeaseLiabilityNoncurrent | Operating Lease, Liability, Noncurrent | USD | 8.43M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | OperatingLeasePayments | Operating Lease, Payments | USD | 2.10M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 |
| us-gaap | OperatingLeaseRightOfUseAsset | Operating Lease, Right-of-Use Asset | USD | 9.92M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDue | Operating Leases, Future Minimum Payments Due | USD | 7.79M | 2018-12-31 | 2019 | FY | 10-K | 2020-03-26 | 0001047469-20-001809 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueCurrent | Operating Leases, Future Minimum Payments Due, Next Twelve Months | USD | 4.65M | 2018-12-31 | 2019 | FY | 10-K | 2020-03-26 | 0001047469-20-001809 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInFiveYears | Operating Leases, Future Minimum Payments, Due in Five Years | USD | 1.52M | 2015-12-31 | 2015 | FY | 10-K/A | 2016-02-25 | 0001047469-16-010396 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInFourYears | Operating Leases, Future Minimum Payments, Due in Four Years | USD | 2.35M | 2016-12-31 | 2016 | FY | 10-K | 2017-03-14 | 0001047469-17-001564 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInThreeYears | Operating Leases, Future Minimum Payments, Due in Three Years | USD | 2.50M | 2017-12-31 | 2017 | FY | 10-K | 2018-03-07 | 0001047469-18-001363 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInTwoYears | Operating Leases, Future Minimum Payments, Due in Two Years | USD | 3.14M | 2018-12-31 | 2019 | FY | 10-K | 2020-03-26 | 0001047469-20-001809 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueThereafter | Operating Leases, Future Minimum Payments, Due Thereafter | USD | 167,000 | 2013-12-31 | 2013 | FY | 10-K | 2014-03-03 | 0001047469-14-001653 | |
| us-gaap | OperatingLeasesRentExpenseNet | Operating Leases, Rent Expense, Net | USD | 4.10M | 2017-01-01 | 2017-12-31 | 2017 | FY | 10-K | 2018-03-07 | 0001047469-18-001363 |
| us-gaap | OperatingLeaseWeightedAverageDiscountRatePercent | Operating Lease, Weighted Average Discount Rate, Percent | pure | 0.1 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 | |
| us-gaap | OperatingLossCarryforwards | Operating Loss Carryforwards | USD | 17.70M | 2016-12-31 | 2016 | FY | 10-K | 2017-03-14 | 0001047469-17-001564 | |
| us-gaap | OtherAccruedLiabilitiesCurrent | Other Accrued Liabilities, Current | USD | 394,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 | |
| us-gaap | OtherAssetImpairmentCharges | Other Asset Impairment Charges | USD | 1.80M | 2019-01-01 | 2019-12-31 | 2021 | FY | 10-K | 2022-02-28 | 0001104659-22-028070 |
| us-gaap | OtherAssetsNoncurrent | Other Assets, Noncurrent | USD | 9.69M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent | USD | 15,000 | 2015-01-01 | 2015-12-31 | 2017 | FY | 10-K | 2018-03-07 | 0001047469-18-001363 |
| us-gaap | OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax | USD | -30,000 | 2015-01-01 | 2015-09-30 | 2015 | Q3 | 10-Q | 2015-11-05 | 0001104659-15-076295 |
| us-gaap | OtherComprehensiveIncomeLossNetOfTax | Other Comprehensive Income (Loss), Net of Tax | USD | -30,000 | 2015-01-01 | 2015-09-30 | 2015 | Q3 | 10-Q | 2015-11-05 | 0001104659-15-076295 |
| us-gaap | OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax | USD | -3.96M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | OtherLiabilities | Other Liabilities | USD | 4.34M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | OtherLiabilitiesCurrent | Other Liabilities, Current | USD | 1.23M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | OtherLiabilitiesNoncurrent | Other Liabilities, Noncurrent | USD | 3.11M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | OtherNoncashIncomeTaxExpense | Other Noncash Income Tax Expense | USD | -529,000 | 2009-01-01 | 2009-12-31 | 2011 | FY | 10-K | 2012-03-08 | 0001047469-12-002276 |
| us-gaap | OtherNonoperatingIncome | Other Nonoperating Income | USD | 1.70M | 2010-01-01 | 2010-12-31 | 2012 | FY | 10-K | 2013-03-08 | 0001047469-13-002403 |
| us-gaap | OtherSundryLiabilities | Other Sundry Liabilities | USD | 39,000 | 2012-12-31 | 2013 | FY | 10-K | 2014-03-03 | 0001047469-14-001653 | |
| us-gaap | OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld | Other than Temporary Impairment, Credit Losses Recognized in Earnings, Credit Losses on Debt Securities Held | USD | 0 | 2023-09-30 | 2023 | Q3 | 10-Q | 2023-11-02 | 0001410578-23-002169 | |
| us-gaap | PaymentsForRestructuring | Payments for Restructuring | USD | 470,000 | 2017-01-01 | 2017-09-30 | 2017 | Q3 | 10-Q | 2017-11-07 | 0001104659-17-066472 |
| us-gaap | PaymentsToAcquireInProcessResearchAndDevelopment | Payments to Acquire in Process Research and Development | USD | 3.50M | 2016-01-01 | 2016-12-31 | 2020 | Q3 | 10-Q | 2020-11-05 | 0001104659-20-121786 |
| us-gaap | PaymentsToAcquireMarketableSecurities | Payments to Acquire Marketable Securities | USD | 524.67M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | PaymentsToAcquireOtherInvestments | Payments to Acquire Other Investments | USD | 1.80M | 2016-01-01 | 2016-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001047469-19-000992 |
| us-gaap | PaymentsToAcquirePropertyPlantAndEquipment | Payments to Acquire Property, Plant, and Equipment | USD | 6.49M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | PreferredStockParOrStatedValuePerShare | Preferred Stock, Par or Stated Value Per Share | USD/shares | 0.01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | PreferredStockSharesAuthorized | Preferred Stock, Shares Authorized | shares | 3.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | PreferredStockSharesIssued | Preferred Stock, Shares Issued | shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | PreferredStockSharesOutstanding | Preferred Stock, Shares Outstanding | shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | PreferredStockValue | Preferred Stock, Value, Issued | USD | 0 | 2022-12-31 | 2023 | Q2 | 10-Q | 2023-08-08 | 0001410578-23-001588 | |
| us-gaap | PrepaidExpenseAndOtherAssetsCurrent | Prepaid Expense and Other Assets, Current | USD | 13.06M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | PrepaidExpenseNoncurrent | Prepaid Expense, Noncurrent | USD | 9.10M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | ProceedsFromIssuanceOfCommonStock | Proceeds from Issuance of Common Stock | USD | 323.83M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | ProceedsFromIssuanceOfDebt | Proceeds from Issuance of Debt | USD | 2.96M | 2020-01-01 | 2020-12-31 | 2022 | FY | 10-K | 2023-02-28 | 0001104659-23-026701 |
| us-gaap | ProceedsFromIssuanceOfLongTermDebt | Proceeds from Issuance of Long-term Debt | USD | -11.03M | 2013-01-01 | 2013-12-31 | 2013 | FY | 10-K | 2014-03-03 | 0001047469-14-001653 |
| us-gaap | ProceedsFromSaleAndMaturityOfMarketableSecurities | Proceeds from Sale and Maturity of Marketable Securities | USD | 391.17M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | ProceedsFromSaleOfProductiveAssets | Proceeds from Sale of Productive Assets | USD | 69,000 | 2022-01-01 | 2022-12-31 | 2024 | FY | 10-K | 2025-02-27 | 0001410578-25-000216 |
| us-gaap | ProceedsFromStockPlans | Proceeds from Stock Plans | USD | 2.27M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | ProfitLoss | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | USD | -20.30M | 2011-01-01 | 2011-06-30 | 2011 | Q2 | 10-Q | 2011-08-04 | 0001104659-11-043630 |
| us-gaap | PropertyPlantAndEquipmentGross | Property, Plant and Equipment, Gross | USD | 29.24M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 | |
| us-gaap | PropertyPlantAndEquipmentNet | Property, Plant and Equipment, Net | USD | 11.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax | Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | RepaymentsOfConvertibleDebt | Repayments of Convertible Debt | USD | 12.50M | 2011-01-01 | 2011-12-31 | 2013 | FY | 10-K | 2014-03-03 | 0001047469-14-001653 |
| us-gaap | RepaymentsOfDebt | Repayments of Debt | USD | 2.96M | 2020-01-01 | 2020-12-31 | 2022 | FY | 10-K | 2023-02-28 | 0001104659-23-026701 |
| us-gaap | RepaymentsOfOtherLongTermDebt | Repayments of Other Long-term Debt | USD | 472,000 | 2013-01-01 | 2013-12-31 | 2015 | FY | 10-K/A | 2016-02-25 | 0001047469-16-010396 |
| us-gaap | RepaymentsOfSecuredDebt | Repayments of Secured Debt | USD | 11.03M | 2013-01-01 | 2013-12-31 | 2015 | FY | 10-K/A | 2016-02-25 | 0001047469-16-010396 |
| us-gaap | RepaymentsOfSubordinatedDebt | Repayments of Subordinated Debt | USD | 2.96M | 2009-01-01 | 2009-12-31 | 2011 | FY | 10-K | 2012-03-08 | 0001047469-12-002276 |
| us-gaap | ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired | Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired | USD | 1.70M | 2016-01-01 | 2016-12-31 | 2020 | Q3 | 10-Q | 2020-11-05 | 0001104659-20-121786 |
| us-gaap | ResearchAndDevelopmentExpense | Research and Development Expense | USD | 207.95M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | RestrictedCashAndCashEquivalentsNoncurrent | Restricted Cash and Cash Equivalents, Noncurrent | USD | 200,000 | 2012-12-31 | 2012 | FY | 10-K | 2013-03-08 | 0001047469-13-002403 | |
| us-gaap | RestructuringCharges | Restructuring Charges | USD | 400,000 | 2018-04-01 | 2018-06-30 | 2018 | Q2 | 10-Q | 2018-08-08 | 0001104659-18-050496 |
| us-gaap | RestructuringReserve | Restructuring Reserve | USD | 200,000 | 2018-09-30 | 2018 | Q3 | 10-Q | 2018-11-07 | 0001104659-18-066648 | |
| us-gaap | RetainedEarningsAccumulatedDeficit | Retained Earnings (Accumulated Deficit) | USD | -2.04B | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | RevenueFromContractWithCustomerExcludingAssessedTax | Revenue from Contract with Customer, Excluding Assessed Tax | USD | 37,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | Revenues | Revenues | USD | 1.76M | 2018-10-01 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001047469-19-000992 |
| us-gaap | RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | USD | 3.50M | 2026-04-01 | 2026-06-30 | 2026 | Q2 | 10-Q | 2026-08-06 | 0001104659-26-091984 |
| us-gaap | RoyaltyExpense | Royalty Expense | USD | 2.33M | 2013-01-01 | 2013-12-31 | 2015 | FY | 10-K/A | 2016-02-25 | 0001047469-16-010396 |
| us-gaap | RoyaltyRevenue | Royalty Revenue (Deprecated 2018-01-31) | USD | 2.33M | 2013-01-01 | 2013-12-31 | 2015 | FY | 10-K/A | 2016-02-25 | 0001047469-16-010396 |
| us-gaap | SecuredDebt | Secured Debt | USD | 10.10M | 2013-03-31 | 2013 | Q1 | 10-Q | 2013-05-03 | 0001104659-13-036833 | |
| us-gaap | SecuredDebtCurrent | Secured Debt, Current | USD | 5.59M | 2012-12-31 | 2013 | FY | 10-K | 2014-03-03 | 0001047469-14-001653 | |
| us-gaap | SecuredLongTermDebt | Secured Long-term Debt, Noncurrent | USD | 5.75M | 2012-12-31 | 2013 | FY | 10-K | 2014-03-03 | 0001047469-14-001653 | |
| us-gaap | SeveranceCosts1 | Severance Costs | USD | 1.20M | 2018-01-01 | 2018-09-30 | 2018 | Q3 | 10-Q | 2018-11-07 | 0001104659-18-066648 |
| us-gaap | ShareBasedCompensation | Share-based Payment Arrangement, Noncash Expense | USD | 27.91M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | pure | 0 | 2022-01-01 | 2022-03-31 | 2022 | Q1 | 10-Q | 2022-05-05 | 0001104659-22-056442 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | pure | 0.98 | 2021-07-01 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-09 | 0001104659-21-136268 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum | pure | 0.98 | 2021-01-01 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-09 | 0001104659-21-136268 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum | pure | 0.97 | 2021-01-01 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-09 | 0001104659-21-136268 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | pure | 0.005 | 2020-07-01 | 2020-09-30 | 2021 | Q3 | 10-Q | 2021-11-09 | 0001104659-21-136268 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum | pure | 0.013 | 2021-01-01 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-09 | 0001104659-21-136268 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum | pure | 0.008 | 2021-01-01 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-09 | 0001104659-21-136268 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized | Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | shares | 7.40M | 2012-09-30 | 2012 | Q3 | 10-Q | 2012-11-02 | 0001104659-12-073441 | |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value | USD | 46.20M | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-06 | 0001410578-24-001766 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | USD/shares | 26.36 | 2024-01-01 | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-06 | 0001410578-24-001766 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value | USD | 15.90M | 2025-06-30 | 2025 | Q2 | 10-Q | 2025-08-07 | 0001410578-25-001610 | |
| us-gaap | StateAndLocalIncomeTaxExpenseBenefitContinuingOperations | State and Local Income Tax Expense (Benefit), Continuing Operations | USD | -5.78M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 |
| us-gaap | StockGrantedDuringPeriodValueSharebasedCompensation | Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture | USD | 250,000 | 2009-01-01 | 2009-12-31 | 2011 | FY | 10-K | 2012-03-08 | 0001047469-12-002276 |
| us-gaap | StockholdersEquity | Stockholders' Equity Attributable to Parent | USD | 649.47M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 | |
| us-gaap | StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest | USD | 92.00M | 2011-06-30 | 2011 | Q2 | 10-Q | 2011-08-04 | 0001104659-11-043630 | |
| us-gaap | StockholdersEquityNoteStockSplitConversionRatio1 | Stockholders' Equity Note, Stock Split, Conversion Ratio | pure | 0.067 | 2019-02-08 | 2021 | FY | 10-K | 2022-02-28 | 0001104659-22-028070 | |
| us-gaap | StockIssued1 | Stock Issued | USD | 71,000 | 2018-01-01 | 2018-12-31 | 2020 | FY | 10-K | 2021-03-29 | 0001104659-21-043161 |
| us-gaap | StockIssuedDuringPeriodSharesNewIssues | Stock Issued During Period, Shares, New Issues | shares | 8.34M | 2015-01-01 | 2015-12-31 | 2015 | FY | 10-K/A | 2016-02-25 | 0001047469-16-010396 |
| us-gaap | StockIssuedDuringPeriodValueAcquisitions | Stock Issued During Period, Value, Acquisitions | USD | 73.40M | 2016-01-01 | 2016-12-31 | 2018 | FY | 10-K | 2019-03-07 | 0001047469-19-000992 |
| us-gaap | StockIssuedDuringPeriodValueEmployeeStockPurchasePlan | Stock Issued During Period, Value, Employee Stock Purchase Plan | USD | 1.11M | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | StockIssuedDuringPeriodValueIssuedForServices | Stock Issued During Period, Value, Issued for Services | USD | 2.00M | 2014-01-01 | 2014-12-31 | 2016 | FY | 10-K | 2017-03-14 | 0001047469-17-001564 |
| us-gaap | StockIssuedDuringPeriodValueNewIssues | Stock Issued During Period, Value, New Issues | USD | 432.30M | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-02-27 | 0001410578-25-000216 |
| us-gaap | StockIssuedDuringPeriodValueOther | Stock Issued During Period, Value, Other | USD | 323.83M | 2026-04-01 | 2026-06-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxBenefit | Tax Cuts and Jobs Act, Change in Tax Rate, Deferred Tax Liability, Income Tax Benefit | USD | 6.90M | 2018-01-01 | 2018-12-31 | 2019 | FY | 10-K | 2020-03-26 | 0001047469-20-001809 |
| us-gaap | TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit | Tax Cuts and Jobs Act, Income Tax Expense (Benefit) | USD | 99.53M | 2017-01-01 | 2017-12-31 | 2019 | FY | 10-K | 2020-03-26 | 0001047469-20-001809 |
| us-gaap | UnrecognizedTaxBenefits | Unrecognized Tax Benefits | USD | 0 | 2016-12-31 | 2016 | FY | 10-K | 2017-03-14 | 0001047469-17-001564 | |
| us-gaap | UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount | Unrecorded Unconditional Purchase Obligation | USD | 4.50M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 | |
| us-gaap | ValuationAllowanceDeferredTaxAssetChangeInAmount | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | USD | -54.75M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 |
| us-gaap | VariableLeaseCost | Variable Lease, Cost | USD | 900,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001104659-26-019652 |
| us-gaap | WeightedAverageNumberOfDilutedSharesOutstanding | Weighted Average Number of Shares Outstanding, Diluted | shares | 74.36M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |
| us-gaap | WeightedAverageNumberOfShareOutstandingBasicAndDiluted | Weighted Average Number of Shares Outstanding, Basic and Diluted | shares | 41.58M | 2021-01-01 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-09 | 0001104659-21-136268 |
| us-gaap | WeightedAverageNumberOfSharesOutstandingBasic | Weighted Average Number of Shares Outstanding, Basic | shares | 74.36M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001104659-26-123322 |